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Abstract 
Background 
Rural Andhra Pradesh is a developing region in India with reported high prevalence of diabetes mellitus and 
blood lipid levels. This is consistent with a worldwide transition of mortality and morbidity towards 
predominantly non-communicable conditions such as heart disease, stroke and diabetes. Detecting and 
monitoring these changes in less accessible regions of the world is a difficult task. 
 
Methods 
Three cross sectional studies examining cardiovascular risk factors in the Godavari region of rural Andhra 
Pradesh were done in 2005 (Andhra Pradesh Rural Health Initiative, APRHI), 2010 (Gates Grand Challenge 13, 
GC13) and 2014 (Systematic Medical Appraisal Referral and Treatment Health, SMARThealth). Diabetes 
prevalence from all three studies and blood lipid levels from 2005 and 2010 were compared to assess the 
trend. The data were further divided into a primary analysis including only fasting plasma glucose 
measurements and a secondary analysis which allowed for other methods of diabetes diagnosis. A systematic 
review and meta-analysis of the use of dried blood spots (DBS) for cardiometabolic risk factor analysis was also 
conducted. 
 
Findings 
Sixteen studies were included in the meta-analysis of the use of dried blood spots, 12 of which reported 
necessary data for haemoglobin A1c (HbA1c), one for triglycerides, two for both triglycerides and total 
cholesterol and one for HbA1c, total cholesterol and high density lipoprotein (HDL).  Study sizes ranged from 30 
to 613 participants.  For HbA1c the summary regression (DBS = 0.9858Venous + 0.3809) showed close 
agreement between analyses based upon the venous and DBS sampling methods.  The summary regression 
line for total cholesterol (DBS = 0.6807Venous + 1.151) indicates a requirement for moderate adjustment of 
values based upon analyses of DBS samples to obtain estimates equivalent to standard analyses based upon 
venous samples.  For triglycerides, the summary regression for the three contributing studies showed a close 
association between the results obtained for the two methods (DBS = 0.9557Venous + 0.1427). 
The primary analyses of dysglycaemia (diabetes and prediabetes) were based upon 3243 individuals from 
APRHI and 749 individuals from SMARThealth for whom fasting plasma glucose samples were available.  The 
estimated prevalence of dysglycaemia was 53.7% (51.8 - 55.7, 95% CI) in 2005 and 62.0% (58.5 - 65.4, 95% CI) 
in 2014 (p<0·001).  The primary difference in population characteristics across the two surveys was a more 
than one unit rise in mean BMI driven by an approximate 1.7kg rise in mean weight.  For the secondary 
analyses there were 3333 individuals aged 40 to 85 included from the APRHI study in 2005; 2200 individuals 
included from the GC13 survey done in 2010; and 62 254 participants included from the SMARThealth  survey 
in 2014.  For the secondary analyses the estimated prevalence of dysglycaemia was 53·9% (52·0 - 55·9, 95% CI) 
in 2005, 50·5% (46.1 - 54.9, 95% CI) in 2010, and 41.3% (40.9 - 41.7, 95% CI) in 2014 with the data suggesting a 
decline across the three time points (p<0.001). There were significant increases observed between 2005, 2010, 
and 2014 for both body mass index (BMI) (p<0.001) and weight (p<0.001). Mean total cholesterol decreased 
from 4.6mM in 2005 to 3.4mM in 2010 while mean low density lipoprotein decreased from 2.9mM to 1.5mM 
during the same period. 
Conclusions 
The use of dried blood spots as a method of reporting HbA1c levels appears justified but further studies are 
required to confirm the suitability of blood lipid level measurements based upon dried blood spots.  Every 
estimate of dysglycaemia was high suggesting that dysglycaemia is a major problem in this part of Andhra 
Pradesh.  Further, the upward trend in dysglycaemia observed in the primary analyses and the corresponding 
adverse trend in obesity measures suggests that the problem is getting worse not better. The differences in 
observed trends between the primary and secondary analyses are almost certainly attributable to the variable 
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assay methods used across the data included in the secondary analyses. The steep changes in lipid levels are 
likely incorrect and have been biased by the study methods. 
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Chapter 1 – Introduction and Literature Review 
Changing disease patterns 
We are currently passing through a notable transition in the history of human health. The most significant 
causes of mortality for hundreds of years are regressing. Previously, infectious diseases, poor pregnancy care 
and childhood undernutrition were the significant conditions plaguing quality of life and premature mortality2. 
Changes in this are due to improvements in basic sanitation and technological advances in health care mainly 
during the 20th and 21st centuries. With this transformation there are a new wave of diseases now responsible 
for the majority of global mortality. Non-communicable diseases now account for over two thirds of global 
mortality3. This includes chronic diseases such as ischaemic heart disease, diabetes and cerebrovascular 
disease. The Global Burden of Disease 2010 study3-7 was paramount to exposing the changing impacts of these 
chronic diseases worldwide. The extensive data generated has provided numerous examples of the 
epidemiological transition to increasing global morbidity and mortality from chronic, non-communicable 
diseases. This is true when viewing the mortality and morbidity attributed to either the specific diseases or 
their risk factors.  
In 1990, ischaemic heart disease and stroke was responsible for one fifth of all mortality and that has increased 
to one quarter in 2010. Similarly, deaths due to diabetes have doubled from 1.3 million worldwide in 19903. 
When measured as disability adjusted life years (DALY) lost, ischaemic heart disease has progressed from 4th to 
1st, stroke from 5th to 3rd and diabetes mellitus from 21st to 14th. Meanwhile lower respiratory tract infections 
fell from 1st to 2nd, diarrhoea from 2nd to 4th, tuberculosis from 8th to 13th, pre-term birth complications from 3rd 
to 8th and protein-energy malnutrition from 9th to 20th 6. Regarding years lost to disability (YLD), the Global 
Burden of Disease study also shows that the main contributors were mental and behavioural disorders, 
musculoskeletal disorders and diabetes mellitus8. These results underline the general transition in global 
health patterns due to demographic changes, changes in cause of mortality and changes in the causes of 
disability. It seems these changes are here to stay and will only continue to drive the transition in the sources 
of disease burden. A World Health Organisation (WHO) forecasting study used simulations that predicted 
deaths from communicable diseases will decline by a further 50% and mortality due to non-communicable 
diseases and injuries will more than double9. 
Another notable epidemiological transition is towards a higher fraction of the total burden of disease 
belonging to disability rather than premature mortality. The causes of disability and mortality are not 
necessarily congruent. Between the top 25 contributors to YLD and the equivalent list for years of life lost, only 
diabetes, road injury, ischaemic heart disease, chronic obstructive pulmonary disease, tuberculosis and 
diarrhoea are found in both groups. Much of this change is attributed to rising rates of diabetes and it has 
been suggested that in today’s age what ails the population the greatest is not always what kills them6. 
Certainly these changes in disease patterns are global but it appears that South Asia is facing an appreciable 
amount of the consequences. Non-communicable diseases have become increasingly prevalent7 as they are 
responsible for almost half of the burden of disease in South Asia10. The rise of cardiovascular diseases in low 
and middle level income countries has been largely unnoticed when compared to the direct threats of 
infectious diseases, although 80% of deaths due to cardiovascular disease now occur in these countries11.  
The combination of poverty and changing cardiovascular disease risk factors is responsible for half of the adult 
burden of disease in South Asia.10 The fact that one quarter of the world population belongs to South Asia and 
that half of those are below the poverty line outlines the significance of the oncoming epidemic of 
cardiovascular diseases. The outcome is evident in India potentially affecting the working age population due 
to the highest numbers of productive years of life lost from cardiovascular conditions. This is a result of the 
excessive deaths due to cardiovascular disease amongst the 35-64 years age group, with 9.2 million life years 
lost in the year 2000 alone. The severity of the situation is clear since this figure is predicted to increase to 17.9 
million years by 2030 which is 940% greater than the corresponding loss of life years in the United States due 
to cardiovascular causes12.  It is also noted that India has the highest absolute number of people with diabetes, 
a contributor to the statistic that 52% of cardiovascular deaths occur below the age of 70, compared to only 
23% in high income countries.  
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Andhra Pradesh is a large state in southern India with a population of 84 million, approximately 70% of whom 
live in rural areas. The Godavari region consists of the East Godavari and West Godavari districts, with a total 
area of 18 509 km2 and a population of 9 million. The region includes the Godavari river delta making it very 
fertile with a large part of the local economy dependent on fisheries and agriculture, including the majority of 
the rice production in the state. This is a rural population susceptible to rapid changes in lifestyle and diet 
where already there are high levels of diabetes, blood lipids, hypertension, smoking and obesity. Most recently 
13.2% were found to have diabetes, 27% hypertension, 7.2% with hypercholesterolaemia and 22.3% 
overweight13, 14. 
Drivers of changing disease patterns 
Non-communicable diseases are increasingly being linked to poverty and socioeconomic disparity. These are 
effects of globalization, urbanisation, demographic and lifestyle changes which are occurring particularly 
rapidly in developing regions of the world. This leads to increasing income gaps and a growing lower middle 
class susceptible to lifestyle related chronic diseases. The wider impact on the countries involved is not trivial. 
From the economic perspective China is estimated to lose the equivalent of $558 billion USD while India is 
estimated to lose $237 billion USD, due to preventable cardiovascular diseases and diabetes over the next ten 
years15.  
A review article in 2004 drew some attention to the then neglected area of chronic disease in India11. The 
author presents a dichotomy of globalization, which is primarily responsible for the accelerating changes in 
developing countries by importing diets and lifestyles from high income countries but at the same time also 
facilitates the prevention of cardiovascular disease through a well-established knowledge base of risk factor 
mitigation. In particular, these epidemics of non-communicable diseases are driven by rapid shifts in 
demographics and lifestyle due to urbanisation, globalisation and industrialisation. These changes have been 
seen in high income countries previously but they occurred over the time span of an entire century rather than 
the few decades the current transitions are compressed into. Also, the rate of urbanisation in areas of 
uncorrected poverty leads to increasing income disparity and will leave the most poor especially vulnerable. 
Considering the health changes associated with urbanisation and socioeconomic status, it has been shown that 
over the previous 20 years the rates of obesity in developing countries have tripled and further and that being 
poorer is coupled to obesity16. The results have been that some families of low socioeconomic status in 
developing regions, such as rural India, have children who are initially underweight but grow to become adults 
who are overweight. The presumption is that intrauterine growth restriction is conferring a predisposition to 
obesity in adulthood. When this possibility is combined with rapid childhood weight gain due to 
overconsumption of cheap, energy-dense food and a lack of physical exercise there exists a platform 
conducive to insulin resistance and the metabolic syndrome. 
More recently in the East and West Godavari regions of rural Andhra Pradesh there has been a focus on 
industrialisation with the development of oil and gas refineries. This is likely to fuel increased economic 
development in the area and potentially further urbanisation17 with which lifestyle and diet changes will 
follow. It is hypothesised that there will be an increase in cardiovascular risk factors including diabetes, total 
cholesterol levels, low density lipoprotein levels and body mass index. This would be consistent with the global 
changes observed over the last 10 to 20 years and is expected of a region undergoing demographic, social and 
economic changes conducive to increasing cardiovascular disease. 
Changing cardiovascular risk factors 
Chronic diseases account for 60% of all deaths and 80% of these are now in low or middle income countries. 
Interestingly the deaths due to chronic diseases in low and middle income countries are also occurring in 
younger age groups when compared to developed countries6. The global burden of disease can be assessed by 
looking at the most significant risk factors for mortality and morbidity. In order to undertake informed primary 
prevention and interventions the risk factors with highest prevalence must be targeted. The top three leading 
risk factors contributing to global disease burden in 2010 were hypertension, tobacco smoking including 
second hand smoke and household air pollution from solid fuels. This is compared to 1990, where the leading 
risks were childhood underweight status, household air pollution from solid fuels and smoking including 
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second hand smoke5.  Hypertension, high body mass index (BMI), high fasting plasma glucose, alcohol use and 
dietary risks have all become more prominent contributors to the global burden of disease during the period 
1990 to 2010. Although, when seen as absolute percentage prevalence, most of these risk factors have actually 
decreased, except high BMI and high fasting plasma glucose.  
Examining the link between risk factors and the diseases impacting the global burden of disease sheds some 
light on where interventions are best focused. ‘Metabolic mediators of the effects of body-mass index, 
overweight and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 
1.8 million participants’ collated the relevant data from 1948 and 2005 and provided the appropriate hazard 
ratios9. The factors linking obesity to cardiovascular disease are clear. A BMI above 25 kg/m2 and over 30 
kg/m2 are both significantly associated with an increased risk for coronary heart disease and stroke when 
compared to the widely accepted normal range of 20 kg/m2 – 25 kg/m2. The adjusted hazard ratios for a 5 
kg/m2 increase in BMI are 1.27 (1.23 – 1.31, 95% CI) for coronary heart disease and 1.18 (1.14 – 1.22, 95% CI) 
for stroke. When further adjusted for elevated blood pressure, cholesterol and glucose, the hazard ratios fell 
to 1.15 (1.12 – 1.18, 95% CI) for heart disease and 1.04 (1.01 – 1.08, 95% CI) for stroke. Blood pressure was the 
prime risk factor, accounting for 31% (28% - 35%, 95% CI) of excess risk for coronary heart disease due to 
increases in BMI and 65% (56% - 75%, 95% CI) of the same for cerebrovascular disease. The principal 
conclusion is that efforts to reduce glucose, total cholesterol and high blood pressure might address 
approximately one half of the excess risk of coronary heart disease and up to three quarters of the excess risk 
of stroke attributed to high BMI. These results were not discriminatory between Asian and western cohorts.  
A 2008 review made some further observations to add to the discussion, predicting that more than half of all 
cases of cardiovascular disease worldwide will be found in India by 202518. The important determinants of 
cardiovascular diseases in India identified here were tobacco use, obesity, a high waist to hip ratio, high blood 
pressure, dyslipidaemia, diabetes, a low fruit and vegetable diet and sedentary lifestyles. It was suggested that 
perhaps genetic factors and a predisposition to diabetes may have a hand in the increase in cardiovascular 
diseases. Therefore it is clear that these risk factors identified globally to be responsible for the majority of 
morbidity and mortality are also responsible for the same health outcomes in India. Considering that 70% of 
India’s 1.2 billion population is rural, it is reasonable to focus efforts on early intervention in areas such as rural 
Andhra Pradesh to negate a potentially massive rise in cardiovascular risk factors. 
Increased fasting glucose levels and diabetes features prominently in both disability and mortality in the Global 
Burden of Disease study and so would be a justified target for interventions both primarily as a risk factor for 
cardiovascular diseases but also as a disease process in itself. Two studies outline the changes and current 
status of worldwide diabetes prevalence and the attempts at controlling incidence. ‘National, regional, and 
global trends in fasting plasma glucose and diabetes prevalence since 1980: a systematic analysis of health 
examination surveys and epidemiological studies with 370 country-years and 2.7 million participants’ provides 
estimated trends in mean fasting plasma glucose and diabetes prevalence for adults aged over 25 in 199 
countries and territories2. This showed that in 2008 the global age-standardised mean fasting plasma glucose 
was 5.5 mM (5.37 mM – 5.63 mM, 95% CI) for men and 5.42 mM (5.29 mM – 5.54 mM, 95% CI) for women 
which is a result of an average 0.07 mM and 0.09 mM increase respectively over every decade since data 
collection commenced. Additionally, the age-standardised diabetes prevalence was 9.8% (8.6% - 11.2%, 95% 
CI) in men and 9.2% (8.0% - 10.5%, 95% CI) in women. This is a significant increase from the 8.3% (6.5% - 
10.4%, 95% CI) and 7.5% (5.8% - 9.6%, 95% CI) respectively seen in 1980. Oceania, in particular, had the most 
significant rise in mean fasting plasma glucose and diabetes prevalence but was only the leader in a closely 
following group of South Asia, Latin America, the Caribbean region, Central Asia, North Africa and the Middle 
East. These trends are distinct from other risk factors for cardiovascular disease such as systolic blood pressure 
which has actually decreased overall in most regions. Notably, there has been an increase in diabetes 
prevalence by about 7% each decade from 1980 and 70% of this increase can be attributed to ageing19. Rising 
adiposity rates are also powering this epidemic and estimate that this would account for much of the 
remaining 30% although there is a significant inter-regional heterogeneity to consider when determining the 
cause for an increase in diabetes in a particular area 20.  
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One set of studies are presented in Table 1-1 with the full selection of diabetes prevalence studies based on 
specific rural regions of India. Another study based on India generally did not focus on specific regions, the 
Prevalence of Diabetes in India Study (PODIS) examined the general population through a random sampled 
multistage cross-sectional survey21, 22. This survey was taken from 1999 to 2002 and was based on clusters of 
local areas and included 18 363 subjects with 7746 of these from rural areas. It is difficult to discern if this was 
a case of simple random or systematic sampling after the clustering stage. The authors also quoted difficulties 
in accurate diagnosis since they could not rely on laboratory venous plasma levels of glucose in many of the 
clusters due to the remote locations. These practical issues underline the need for improved epidemiological 
techniques for measuring such analytes and are further discussed in chapter 3. The results from PODIS showed 
the total Indian diabetes prevalence was 4.3% (4.0% - 4.6%, 95% CI) with 5.6% (5.1% - 6.0%, 95% CI) urban and 
2.7% (2.3% - 3.1%, 95% CI) in rural areas. The corresponding rates of impaired glucose tolerance were 5.2% 
(4.9% - 5.5%, 95% CI), 6.3% (5.8% - 6.8%, 95% CI) and 3.7% (3.3% - 4.1%, 95% CI). Based on these results the 
authors advocated for a diabetes action or prevention program carefully focussing on the rural segment where 
more than 70% of the population lives. These people are also the most vulnerable to the insidious effects of 
chronic disease.  
TABLE 1-1. PREVIOUS RURAL INDIAN STUDIES ON DIABETES PREVALENCE. 
Study  Region Sample Size Diabetes Prevalence 
(95% CI) 
Ramachandran 198923 Tamil Nadu 1038 2.4% 
Patandin 199424 Tamil Nadu 467 4.9% 
Wander 199425 Punjab 809 4.6% 
Singh 199826 Uttar Pradesh 1769 2.8% 
Raghupathy 200227 Tamil Nadu 1221 2.1% 
Balagopal 200328 Tamil Nadu 703 5.1% 
Ramachandran 200329 Tamil Nadu 1213 6.36% (4.89-7.83) 
Nirmalan 200430 Tamil Nadu 5150 4.4% (3.8-5.0) 
Chow 200431 Andhra Pradesh 345 3.7% (1.8-5.5) 
Chow 200514 Andhra Pradesh 4535 13.2% (12.1-14.3) 
Ramachandran 200632 Tamil Nadu 2584 9.2% (8.0-10.5) 
Kokiwar 200733 Nagpur 924 3.67% 
Vijayakumar 200734 Kerala 1645 12.5% 
Khatib 200835 Maharashtra 306 8.4% 
Jonas 201036 Central India 2414 5.6% (5.1-6.1) 
Vaz 201137 Goa 1266 10.3% 
Madaan 201438 Haryana 4497 18.43% 
 
Table 1-1 is similar to a previous table presented in “Review of the epidemiology of diabetes in India”39 
although here it is updated to 2014 and includes the study year rather than the publication year where 
available. Included are studies surveying populations using fasting blood sugar, oral glucose tolerance test or 
glycosylated haemoglobin (HbA1c) as their diagnostic method. Also included are confidence intervals where 
possible, this is in addition to the previous publication. This table is also restricted to studies involving only 
specific rural populations, excluding urban studies or rural/urban mixed groups. The regional disparities in 
diabetes prevalence are evident, underlining the need for area specific studies if a registry system is not 
otherwise available. Only the studies in Tamil Nadu by Ramachandran et al. involved follow up of a series of 
results from the same area, their results are shown in figure 1-1. Otherwise, there is little information about 
the changing diabetes prevalence in each of these specific areas. By revisiting this rural region of Andhra 
Pradesh, valuable insight can be gained into the changes in diabetes in an area which has already shown an 
alarmingly high diabetes rate. The progress of the diabetes epidemic in rural areas can be elucidated further 
and the trend for diabetes prevalence can be identified as either stable, accelerating or potentially 
decelerating.  
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The directly relevant preceding studies in Andhra Pradesh were done by Chow et al. using the data gathered 
from APRHI in 2005. This involved a series of publications regarding cardiovascular risk factors in the Godavari 
region of rural Andhra Pradesh. It is these data that is being used as a baseline for comparisons with the GC13 
and SMARTHealth results in this study. In an initial pilot study for the project, data were collected from two 
villages in June 2004 using a simple random sample after stratification by age and sex groups. The data 
collection was based on a questionnaire, physical measurements and a fasting venous blood sample. The 
authors concluded from the high quality of the data obtained that it was feasible to continue and conduct 
larger studies in the region31. ‘Significant lipid, adiposity and metabolic abnormalities amongst 4535 Indians 
from a developing region of rural Andhra Pradesh’ showed a prevalence of metabolic syndrome of 24.6% 
(21.7% - 27.5%, 95% CI). When the specific Asian definition of metabolic syndrome was used, this increased to 
30.2% (27.1% - 33.3%, 95% CI)13. In this paper this was defined as a waist circumference 12 cm (men) and 8 cm 
(Women) lower than the general definitions of an increased waist circumference.   ‘Fatal and nonfatal 
cardiovascular disease and the use of therapies for secondary prevention in a rural region of India’ found a 
combined prevalence of coronary heart disease and stroke at 6.6% (5.8% - 7.4%, 95% CI). The mean age of 
cardiovascular disease incidence was 54 years (52 – 55, 95% CI). ‘The prevalence and management of diabetes 
in rural India’ was also based on the same data and showed a diabetes prevalence of 13.2% (12.1% – 14.3%, 
95% CI) with a further 15.5% (14.2% – 16.8%, 95% CI) with impaired fasting glucose. These results from the 
APRHI study provide a background understanding of the already high rates of cardiovascular disease risk 
factors in this region.  
A recent large study of 14 277 urban and rural adults examined the state of lipid levels in four Indian regions,  
determining that dyslipidaemia is extreme in India and calls for urgent lifestyle interventions for prevention 
and management of cardiovascular disease40. Almost 80% of the general population showed abnormalities in 
at least one of total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) or triglycerides 
with no urban to rural differences. Specifically the highest rates of high LDL cholesterol (15.8%) and high total 
cholesterol (18.3%) were found in Tamil Nadu, the neighbouring state to Andhra Pradesh. The equivalent 
preceding study for blood lipids in rural Andhra Pradesh was also by Chow et al.13. It was concluded that the 
metabolic risk factors highly prevalent in this population are focal in the foundation of cardiovascular disease 
in the region.  
FIGURE 1-1. DIABETES PREVALENCE IN A SELECTED REGION OF RURAL TAMIL NADU AS MEASURED BY 
RAMACHANDRAN ET AL. AN EXPONENTIAL TRENDLINE IS FITTED AS AN APPROXIMATION TO THE TREND. 
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Approaches to risk factor measurement 
One of the difficulties when collecting data for rural, resource poor regions is attaining biological specimens. 
Unfortunately this is necessary when researching cardiovascular risk factors since questioning the population 
on prior diagnoses of diabetes or hypercholesterolaemia will significantly underestimate prevalence due to 
lack of awareness and undiagnosed cases. Currently, to assess diabetes and hypercholesterolaemia, venous 
blood samples via venepuncture are required and fasting blood glucose and cholesterol levels are measured. 
This presents challenges of collector training, safety, samples storage and participant willingness. A possible 
alternative to this is using dried blood spots (DBS). This is a spot of blood collected on paper which can be used 
for the same purposes as a full venepuncture sample. DBS was first used by Robert Guthrie to screen 
newborns for phenylketonuria41 and now has become more widespread to include large proteins such as 
insulin and antibodies, DNA sequences and various markers of metabolic diseases42. The primary issue with 
DBS measurements has been sensitivity to detect minute amounts of the analyte since the amount of blood 
available is small. There has been progress with the increasing sensitivity of biochemical analysis techniques 
such as high performance liquid chromatography or immunoturbidimetry. Collecting the DBS itself only 
involves disinfection, pricking the site with a lancet, collecting the blood drop on filter paper, drying, extraction 
and then biochemical analysis42. This requires far less of both the blood collector and the patient when 
compared to a traditional venepuncture to obtain larger blood samples. There are many other perceived 
benefits to using DBS over venepuncture samples. There are lower costs and more ease with storing the 
samples. It is unusual for the analysis centre to be in close proximity to the field where the specimens are 
collected and so a period of storage and transportation are usually necessary. Many more DBS samples can be 
stored with minimal disruption as there are no glass containers or liquid samples, there is a lower chance of 
losing samples to breakage during transportation. DBS also has a lower infectious risk with no liquid samples 
and with the breach of skin with a sharp being uncoupled from the collection of the sample, therefore having 
lower risk of needle-stick injuries. All of these advantages present DBS as an attractive option for biological 
specimen collection in such settings as rural villages in Andhra Pradesh.  
Another adjustment to consider is the use of HbA1c rather than fasting or random blood glucose for diagnosing 
diabetes. This is more convenient as it avoids having to ensure that participants are fasted and so is beneficial 
for both specimen collectors and the participants. The HbA1c is representative of the glycaemic status of the 
participant over the previous three months and so is less affected by day to day variation. Therefore it is also 
more useful than random blood glucose measurements which will vary depending on the timing of the last 
meal.  
The existing diagnostic criteria for diabetes using HbA1c do not account for DBS, they are based on 
venepuncture blood samples of HbA1c. These current definitions of diabetes and prediabetes are based 
primarily on studies examining the rate of diabetes related complications from increasing blood glucose or 
HbA1c levels43. Table 1-2 provides the currently accepted definitions. It is also reasonable to group both 
diabetes and prediabetes as dysglycaemia in general. This is useful when working with studies which employ 
different diagnostic methods as none of the methods are completely concordant with each other. 
TABLE 2-2. DEFINITIONS OF DIABETES AND PREDIABETES FROM ‘DIAGNOSIS AND CLASSIFICATION OF DIABETES 
MELLITUS’43. 
 Fasting Blood Glucose 2- hour or Random 
Blood Glucose 
HbA1c 
Prediabetes 5.6 mM – 6.9 mM 7.8 mM to 11 mM 5.7% - 6.4% 
Diabetes > 7 mM > 11.1 mM > 6.5%  
 
 
Unfortunately the data regarding the use of DBS for cardiometabolic analytes such as HbA1c and blood lipids 
was sparse. There was no consensus on the appropriate use of the technique for these specific analytes even 
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though DBS has been studied and validated in many other fields. Much of the current progress with DBS use 
has been presented in a review paper44 which did not have adequate conclusions on the use of DBS for the 
analytes of interest here. The 2005 APRHI and 2014 SMARTHealth surveys used venous blood sampling 
whereas the 2010 GC13 survey used dried blood spots. It was therefore necessary to collate these data and 
critically analyse the current literature in the form of a systematic review and meta-analysis before the results 
of GC13 were to be correctly analysed and published. This review aimed to identify the relationship between 
DBS and venous samples of cardiometabolic blood analytes and possibly provide a robust conversion equation 
to account for any systematic differences between the measures. Also the current literature on DBS for these 
analytes makes use of a variety of biochemical assays and storage conditions. The effects of these variables 
also need to be ascertained. The results of this study can have a significant effect on the field due to 
expedition of future large surveys such as in GC13.  
In addition to specimen collection technique and diagnostic criteria for the disease of interest, the choice of 
survey methodology is important. Particularly in rural regions of the less developed countries, there may be 
difficulties in achieving robust data to adequately assess the epidemiology of diseases. The most ideal 
approach would be a full sample of every member of a target population. This is obviously impractical. Simple 
random sampling and systematic random sampling are reasonable alternatives but are effected by biases 
depending on the accessibility of villages and availability of participants. For example, during data collection, 
certain demographics may be away from home due to work etc. Post-stratification to a population standard 
can negate some of these biases by weighting the sample estimates to adjust a sample demographic to the 
population demographic. This requires up to date demographic data for the general population, such as a 
census. Simple random sampling could be conducted by random house visits or phone calls to members of a 
census list. Systematic random sampling would be to visit every nth household in a selection of villages. Both of 
these unfortunately are very resource intensive, therefore limiting the potential sample size. For a more 
practical approach, clustered sampling can be used45. This involves selecting groups of households within 
villages. The potential bias here is that the standard error estimates may be artificially reduced due to 
similarities within clusters. For example, a group of households in close proximity may have more similar diets 
than a random selection of households would. To counter this, the standard error estimates are adjusted using 
various estimation techniques such as Taylor Linearization which provide more appropriate estimates for 
standard error. Post-stratification weighting can also be combined with a cluster sampling approach to 
mitigate the same demographic related biases as were discussed with simple random and systematic random 
sampling. 
Discussion 
Currently there are few studies examining the state of cardiovascular risk factors in the rural Indian 
population46. It is also noted that there have been only eleven previous studies of coronary heart disease in 
rural India even though the current limited data shows coronary heart disease and stroke have increased 
incidence in both urban and rural India. For the rural population of 876 million this is not sufficient. This 
information is essential in characterizing the state of cardiovascular disease and its risk factors in India as the 
majority of the population is considered rural. The implication is that any change in the disease burden of the 
rural population will have a magnified effect on India and its economy in general. Of course it is more efficient 
to target the problem in its initial stages but before effective and informed preventative measures can be 
contemplated, the full extent of the problem must be assessed47. This needs updated investigations and 
monitoring of the changing trends in disease burden which is part of the premise for this project. Appropriate 
choice of specimen collection technique and survey method can make this complex task more manageable.  
Unfortunately, of the currently available studies there are some significant regional disparities in the precise 
nature of the cardiovascular risk factor profiles48. This heterogeneity will also have implications on health 
policy, particularly in deciding on the most cost-effective interventions for a particular population. The path to 
identifying the accurate risk factor profiles of populations affected by the rise of cardiovascular disease is 
further observational studies. Studies of generally large areas such as states or countries can inform health 
policy to a certain extent. Further optimization of public health primary prevention policies and initiatives will 
be possible with detailed study of a region and its particularities. This is especially necessary when referring to 
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resource poor locations which are economically constrained to fulfil health recommendations and cannot 
afford to focus on risk factor reductions that may have a minimal effect for that population. Rather, it would 
be desirable to target the top cardiovascular disease risk factors responsible for the greatest portion of the 
total morbidity and mortality plaguing a particular society. These gaps in the data need to be adequately 
addressed to facilitate the required optimal interventions.  
As it stands, India has made progress in effective cardiovascular disease monitoring with the implementation 
of a web based National Stroke Registry in 201349, 50. This will provide data on stroke incidence and prevalence 
and can influence primary, secondary and tertiary prevention. The caveat to this is that to adequately assess 
primary prevention strategies, data on both cardiovascular events and cardiovascular risk factors is necessary. 
In the absence of national registries collecting regular data on cardiovascular risk factors, the options for more 
focused regional cardiovascular risk factor study are left to individual surveys of selected regions. These 
studies in Chapters 4 and 5 can serve as varied examples of cost-effective and efficient approaches to data 
collection in resource poor, rural but populous regions at risk of cardiovascular disease.  
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Chapter 2 - The Three Surveys 
Three large scale cross-sectional studies, APRHI (2005), GC13 (2010) and SMARTHealth (2014) were analysed. 
In particular, the population diabetes prevalence from the three surveys were compared. Total cholesterol 
levels and low density lipoprotein (LDL) levels were also compared between APRHI and GC13. The 
methodology of the APRHI survey has been described previously13, 14, 46, 51, 52. 
APRHI 
Setting and Survey Sampling 
This was based on 20 villages in West and East Godavari. The participants were prestratified into age and sex 
strata and then sampled using simple random sampling within each age and sex stratum in each village. The 
full survey is found in Appendix 2. Those aged 30 and above were included. 
Specimen Collection 
APRHI used fingerprick blood glucose samples and the majority of participants were fasting. The fasting or 
random blood glucose criteria, and previous history of diabetes or diabetic medication use were used to 
diagnose participants as having diabetes. 
Weighting of Data 
Due to potential bias introduced by the simple random sampling method, post-stratification weights were 
used in APRHI to ensure the sample demographics were adequately representative of the larger population 
demographics. These post-stratification weights were based on age/sex demographic data collected on the 
larger background population in the form of a census in 2004. Without these weights the demographic of the 
sample could be significantly different from the true demographic of the villages. 
GC13 
Setting and Survey Sampling 
In GC13 the study population included 14 villages in the Godavari region of rural Andhra Pradesh, India. These 
data were collected as a part of the Population Health Metrics Research Consortium Project in Andhra 
Pradesh, India under the Gates Grand Challenge-13 initiative. The aim of the overall project was to develop 
robust methods to measure mortality rates where vital registration systems are incomplete. The hypothesis 
was that the methods for estimating mortality rates in the population can be developed with suitable 
techniques surveying a subset of the population. This involved a census and household surveys. The census 
covered 45 villages and 180,000 people in total and the subsequent household survey covered a small 
subpopulation of this. Data were collected from those aged 15 and above. The data presented in this study is 
derived from this household survey collected in 2010. The surveys offered to each individual participant were 
divided into separate modules composed of household demographics, household mortality, coverage and 
verbal autopsy. This study focused further on the data available from the coverage module which included 
disease specific questions and physical measurements. The relevant sections of the survey are found in 
Appendix 3.   
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Specimen Collection 
In GC13 dried blood spots (DBS) were collected for each participant involved at the final stage of selection. The 
participant’s finger was pricked with a lancet and after allowing a first drop to pass, the second drop was 
collected on a piece of filter paper. These samples were dried for two to three hours and placed in a plastic bag 
for storage at 4oC for 10 days maximum. They were transported to the Nizams Institute for Medical Sciences in 
Hyderabad, Andhra Pradesh. The glycosylated haemoglobin (HbA1c) was eluted from the filter paper 
specimens and analysed by immunoturbidimetry using the Randox Latex Agglutination Inhibition Assay, 
Randox Laboratories Ltd.  
Post-Analysis Adjustment 
The numerical results from the biochemical analysis of DBS for HbA1c were adjusted using the regression 
equation derived in Chapter 3. This allowed correction for factors that alter HbA1c measurements due to the 
use of DBS over a venepuncture sample. The diagnostic criteria for diabetes and prediabetes have only been 
FIGURE 2-0-1. GC13 SURVEY STRUCTURE. SRS = SIMPLE RANDOM SAMPLING, PSU = PRIMARY SAMPLING UNIT, SSU = 
SECONDARY SAMPLING UNIT, DBS = DRIED BLOOD SPOT. 
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validated for venepuncture samples of HbA1c43 and so appropriate adjustment of DBS samples was required as 
per the results in Chapter 3. 
Weighting of Data  
GC13 data would be expected to have some bias due to the survey structure. To account as such post-
stratification weights and inverse probability of selection weights were used. These post-stratification weights 
were based on age/sex demographic data collected on the larger background population using data from the 
census in 2010. The inverse probability of selection weights work to counter the increased likelihood of 
selecting an individual who belongs in a village with fewer households and/or a household with fewer people. 
Without these weights the results would be biased towards those who live in smaller villages/households. This 
is a result of the clustered survey structure. 
SMARTHealth 
Setting and Survey Sampling 
The survey conducted in 2014 was much larger than both APRHI and GC13 with 62 254 adults. The West 
Godavari district is divided into multiple primary health care centres (PHC), 18 of which were selected as 
representative of the region. Within each PHC, three villages were selected by simple random sampling. A 
census list was compiled for the 54 villages and every household was visited with participants aged between 
40 and 85 included in the survey. There was no sampling at the individual level. The probability of selection 
was equal for each individual. The aim in this survey was to gather simple census data than detailed surveys of 
each member in a limited sample. 
Specimen Collection 
SMARTHealth used blood glucose levels from fingerprick point of care samples. The majority of participants 
were non-fasting with > 6 hours of no oral intake considered to be fasting. The fasting or random blood 
glucose criteria, and previous history of diabetes were used to diagnose participants as having diabetes. 
Weighting of the Data 
SMARTHealth was a considerably large survey of 54 villages in West Godavari. Due to the extent of this survey 
with 62 254 participants, it was considered that no particular weighting of the data was required as it could be 
almost considered a population census in itself. 
Discussion  
The GC13 survey was structured as a stratified clustered sampling method. This is in contrast to a theoretically 
ideal simple random sampling survey which is logistically more difficult to perform and less easy to achieve a 
reasonable sample size53-55. The full survey structure is demonstrated in figure 2-1. The use of such sampling 
methods has been well studied and, if accounted for appropriately, then should yield results similar to a 
corresponding simple random sample53, 56. There are three levels of statistical consideration required for this 
survey. The initial stratification into villages, the multistage clustered sampling and the final post-stratification 
adjustments for age and sex demographics. Sampling from within strata independently acts to reduce the 
sampling error by increasing the representation from all the different groups, in this case the villages. This 
allows for a weighted mean which can have a lower variance than the arithmetic mean derived from simple 
random sampling which may under-sample certain villages by chance.  
The two main issues encountered with a clustered survey structure are the probability of selection of an 
individual and the calculation of the variance of the sample statistics. The probability of selecting an individual 
in a simple random sample is equal between each participant. In contrast, the probability of selecting an 
individual in such a multistage clustered survey will depend on the proportion of clusters sampled and the 
proportion of participants sampled within that participant’s cluster. This can reliably be accounted for by 
weighting the data from each participant appropriately as is explicitly demonstrated in chapter 4. The resulting 
weights are known as inverse probability of selection weights. The second issue is regarding variance which 
will affect the significance level of any results found. The clustered survey will have a higher variance, once the 
survey structure is correctly accounted for, when compared to an equivalent sample size in a simple random 
sample. This is known as having a design effect greater than 1. This dilated variance can be lessened by 
 Page 17 of 93 
 
increasing the sample size in a clustered sampling to achieve the same variance as that of a simple random 
sample. For example, assuming a design effect of approximately 2, the variance of a clustered survey will be 
equal to the variance of a simple random sample which has half the sample size. The design effect itself is a 
function of cluster size and intra-cluster correlation, Deff = 1 + (Cluster size – 1)*(Intra-cluster correlation)55. 
Therefore the optimal clustered survey will have a minimal cluster size and maximum intra-cluster variation. Of 
these, only the cluster size is in the control of the investigators and here it is the size of the household for the 
primary sampling units and then the number of participants selected within each household for the secondary 
sampling units. In this survey the number of participants selected within each household was only one and so 
the cluster size at the second stage was at a minimum. Unfortunately the cluster size of the households is not 
within the investigator’s control in this case.  
The third statistical adjustment is the post-stratification weighting after the simple random selection of 
participants for DBS. Here, the final data from each participant is weighted according to the discrepancy 
between the sample age and sex proportions and the population age and sex proportions. Of course for this to 
be feasible the population demographics are required and so the census data for the Godavari region was used 
in this case. This adjustment aims to ensure correct representation of the age and sex dependence of the data 
according to the population age and sex distribution. This is in case the sample has a different age and sex 
distribution to the overall population, this can then be corrected for to ensure that the data is not skewed due 
to the random selection of participants for dried blood spots. This post-stratification weighting was also used 
in the APRHI analysis. APRHI did not need inverse probability of selection weights since it only employed 
simple random sampling with no clusters.  The variances of the means and proportions calculated were 
appropriately estimated using the Taylor Linearization Method through the STATA ‘svy’ command. Further 
methodological detail is found in chapter 4.  
TABLE 2-1. SUMMARY OF THE SURVEY METHODOLOGY OF ALL THREE STUDIES. 
Study n Region Villages  Survey Structure Data Weights Specimen 
Collection 
APRHI 2005 4535 East and West 
Godavari 
20 Stratified Simple 
Random 
Sampling 
Post-stratification 
weights 
Fingerprick 
Blood 
Glucose 
GC13 2010 2991 West Godavari 14 Stratified 
Clustered 
Random 
Sampling 
Post-stratification 
weights and inverse 
probability of 
selection weights 
DBS HbA1c 
SMARTHealth 
2014 
62 254 West Godavari 54 Full Sampling None Fingerprick 
Blood 
Glucose 
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Chapter 3. Comparability of HbA1c and lipids measured with dried 
blood spots versus venous samples: a systematic review and meta-
analysis  
 
Publication Details: Eshan T Affan, Devarsetty Praveen, Clara K Chow, and Bruce C Neal. BMC Clin Pathol. 
2014; 14: 21 
Author Contributions: Eshan Affan was the principal investigator, designed the study, organized the literature 
review, analysed and presented the results and formed the main body of the text. Devarsetty Praveen was a 
secondary reviewer of the abstracts isolated for studies to be included in the meta-analysis. Clara Chow 
reviewed and provided guidance for the structure of the study. Bruce Neal oversaw the design of the study, 
edited and reviewed the publication. 
INTRODUCTION 
Cardiovascular diseases57 are increasing particularly rapidly in developing country settings with diabetes a key 
determinant of risk58.  Documenting the role of dysglycaemia and other metabolic risk factors59-64 can be 
challenging in these countries because the infrastructure and resources required to conduct research are 
limited.  For example, assays of glycosylated haemoglobin (HbA1c) and blood lipids are usually done on venous 
blood samples which can be difficult to collect, transport and store.  The use of dried blood spot (DBS) 
sampling65, 66 is one possible solution.  DBS involves pricking the participant’s finger with a lancet and collecting 
drops of blood on a piece of filter paper. Samples are then dried and placed in sealed plastic bags for 
transportation and storage67, 68. Compared to venous samples, collecting DBS requires minimal training of staff, 
is cheaper, is safer, provides for simpler transportation and is more acceptable to study participants68-71. 
DBS samples are now widely used for measuring serum antibodies, human immunodeficiency virus (HIV) loads 
and blood hormone levels with good data to define the comparability of results between analyses based upon 
DBS and standard venous samples67, 70, 72, 73.  The absence of comparable data to define the associations for 
HbA1c and blood lipids means that DBS samples are not widely used in studies making assessment of 
cardiovascular risks.  The objective of this project was to synthesise the available evidence describing the 
comparability of findings for assays of HbA1c and blood lipids based upon DBS samples compared to standard 
venous samples. 
MATERIALS AND METHODS 
This project was a systematic review and meta-analysis done to define the association of findings for HbA1c 
and blood lipids for analyses based upon standard venous samples compared to DBS samples. This was a 
secondary analysis of existing published data and no ethics review was therefore required. 
Search strategy 
The Cochrane, Embase and Medline databases were searched electronically during July 2012 using 
combinations of the terms “dried blood spot”, “dried blood”, “DBS”, “filter paper”, “triglycerides”, 
“triacylglycerides”, “HbA1c”, “glycosylated haemoglobin”, “glycated haemoglobin”, “cholesterol”, “high 
density lipoprotein”, “HDL”, “low density lipoprotein” or “LDL”.  Additional studies were identified by a manual 
examination of the reference lists of all studies identified as eligible. 
Eligibility criteria 
Studies were eligible for inclusion if they directly compared values generated from analyses based on DBS 
samples to analyses based on venous samples.  To be included, a study had to report in the form of a 
regression equation an association for one or more of the specified outcomes.  There was no restriction on the 
type of study population. 
Data extraction 
Two independent observers reviewed the abstracts for eligibility and extracted standardised data into a data 
collection sheet for eligible studies.  The data sought from each study were based upon a comparable prior 
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systematic review done in the HIV field 73 and included: date of publication, study size, participant 
characteristics and sample storage conditions. For each risk factor reported upon we sought to identify the 
laboratory extraction method, biochemical assay method and regression coefficient.  Where available we also 
noted data describing the stability of the DBS samples. 
Outcomes 
The outcomes studied in this overview were HbA1c, total cholesterol, high density lipoprotein (HDL) 
cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. 
Statistical analysis 
The characteristics of included studies were summarised in tabular form (Table 3-1).  The linear regression 
coefficients from each study were pooled separately for each risk factor using a weighted least squares 
approach74 to estimate an overall coefficient.  The same method was used to estimate a combined intercept.  
This gave a relationship of the form: DBS = bVenous + a where ‘b’ is the combined coefficient and ‘a’ is the 
combined intercept.  The synthesis of the parameters was done as follows:  
 
 
 
Where weight wi = the number of participants in study i, and bi and ai represent the coefficient and intercept, 
respectively, for the regression line in study i. 
Heterogeneity of the individual study estimates contributing to each meta-analysis was assessed using the 
Cochran’s Q and I2 statistics.  Subsidiary analyses were done to explore the impact of assay method for the 
outcome of HbA1c. 
RESULTS 
There were 705 records identified by the electronic search for which abstracts were reviewed.  Six further 
studies were found by the manual search of reference lists for included studies (Figure 3-1).  One final study 
was found during the review process. Sixteen studies were ultimately included in the meta-analysis, 12 of 
which reported necessary data for HbA1c, 1 for triglycerides, 2 for both triglycerides and total cholesterol and 1 
for HbA1c, total cholesterol and HDL (Table 3-1, Table 3-2)65, 66, 75-89.  One other study of HbA1c was excluded 
because it did not provide a regression equation90 and one other study of triglycerides was excluded because it 
did not provide the sample size88. There were no studies reporting data for LDL-cholesterol identified. 
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The total numbers of participants providing data were 1425 for HbA1c, 773 for triglycerides and 1093 for total 
cholesterol.  Study sizes ranged from 30 to 613 participants.  The assay methods varied for HbA1c which 
included immunoturbidimetric, high performance liquid chromatography (HPLC) and affinity chromatography 
assays but all studies measuring triglycerides, total cholesterol and HDL used colorimetry. 
 
HbA1c 
For HbA1c the summary regression (DBS = 0.9858V + 0.3809) (Figure 3-2) showed close agreement between 
analyses based upon the venous and DBS sampling methods.  There was, however, evidence of heterogeneity 
between the contributing regression lines for the intercepts (Cochran’s Q-test p<0.001 and I2=98%) but not the 
slopes (p= 0.833 and I2=0%). Subsidiary analyses by assay method showed that the heterogeneity was partially 
attributable to different results for the two studies that used affinity chromatography.  Funnel plots did not 
provide clear evidence of publication bias (Figures 3-5 and 3-6). 
Blood lipids 
The summary regression line for total cholesterol (DBS = 0.6807Venous + 1.151) (Figure 3-2) indicates a 
requirement for moderate adjustment of values based upon analyses of DBS samples to obtain estimates 
equivalent to standard analyses based upon venous samples.  The regression lines for the two studies 
contributing to this meta-analysis were directly comparable in terms of both slope and intercept although both 
were derived from studies done at the same investigational centre.  For triglycerides, the summary regression 
for the three contributing studies showed a close association between the results obtained for the two 
FIGURE 3-1 FLOW CHART DETAILING IDENTIFICATION OF STUDIES1 
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methods (DBS = 0.9557Venous + 0.1427) (Figure 3-2) without any evidence of heterogeneity between the 
three results. Only one data set was available for HDL. 
Storage 
Data about the circumstances and duration of storage of DBS samples were inconsistently reported with few 
data to describe whether the analysis findings were affected by extended storage duration or different storage 
temperatures.  From the limited data available it was concluded that DBS samples collected for assay of HbA1c 
and intended for HPLC analysis can be stored for 5 days at room temperature or for up to 3 years at -70°C65, 67, 
77.  If analysis by immunoturbidimetry is planned, the data variously suggest that samples can be stored safely 
at room temperature for up to 44 days66, at 4°C for up to 15 days81 and storage at -80°C for up to 3 months.76  
For total cholesterol samples were reported as stable for up to 1 month at room temperature82, 89 and up to 3 
months at 4°C89, and for triglycerides up to 1 month at room temperature and up to 2 months at 4°C82. 
FIGURE 3-2. INDIVIDUAL (SOLID) AND SUMMARY (DOTTED) REGRESSION LINES SHOWING THE ASSOCIATIONS BETWEEN 
RESULTS FOR ANALYSES BASED UPON DRIED BLOOD SPOT (DBS) COMPARED TO VENOUS (V) SAMPLES FOR HAEMOGLOBIN 
A1C (HBA1C) ANALYSED BY ANY METHOD (A), HBA1C ANALYSED BY SPECIFIC METHODS (B TO D), TRIGLYCERIDES (E) AND 
TOTAL CHOLESTEROL (F).  - THICKNESS OF LINE INCREASES WITH SAMPLE SIZE.  LINE LENGTH WAS DEFINED AS ±1 
STANDARD DEVIATION (SD) OF THE STUDY (OR OVERALL) MEAN.  WHERE THE MEAN OR SD OF A STUDY WAS NOT 
AVAILABLE THE AVERAGE FOR THAT ANALYSIS WAS USED. 
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DISCUSSION 
These analyses identified clear associations between assay results based upon blood samples collected using 
traditional venous approaches and blood samples collected using DBS techniques, for both HbA1c and selected 
blood lipids.  The data provide a strong rationale for the further investigation of DBS sample collection 
techniques although also serve to highlight a number of areas that require further exploration before the 
method is considered mainstream in this field.  If, however, standards and calibrations can be agreed, as has 
been achieved in other fields of research 77, 83, 91, the DBS method does appear to have significant potential to 
address the logistical challenges of venous sampling for studies of metabolic risks in resource poor settings73. 
The differences between the intercepts of the regression lines obtained for the various analytic methods used 
for assay of HbA1c require careful consideration in terms of their implications.  If the variation is due to the 
analytic method selected then it will be necessary to recommend a standard approach for each analyte of 
interest.  However, while the analytic method is the obvious explanation for the observed variation it is not 
possible to exclude alternative causes on the basis of the available data. For example, other aspects of the 
preparation of the DBS samples such as transportation and extraction were not standardised across the 
different analytic methodologies and might also be a cause of the differences noted.  
The incomplete and summary nature of the data available for analysis placed significant constraints upon the 
extent to which the results could be explored in this overview.  In particular, measures of variance of the data 
were unavailable for most contributing studies, requiring that weighting be done by sample size alone 74 with 
consequent limitations upon the methodologies that could be used to present uncertainty intervals around 
both the individual studies and the summary estimates. For example, we identified a possible relationship 
between the regression parameters and the mean HbA1c of the contributing studies suggesting that both the 
intercept and the slope might change when HbA1c rises above 8% (Figures 3-3 and 3-4).  This implies a non-
linear association of venous with DBS sample results that might require a more nuanced explanation than the 
simple linear regressions provided here 65. Removing the studies with high average HbA1c levels from the 
meta-analysis resulted in a regression line approaching parity (DBS = 0.9553V + 0.2566) and with a reduced 
heterogeneity for both the slopes (I2=0%) and the intercepts (I2=92%).  However, whether this simply reflects a 
chance finding in the data, or a true variation of the association by mean HbA1c level is still uncertain.  
Likewise, several studies used the same patients for two rounds of analysis 78, 87 and there would therefore 
have been some correlation between the findings for each.  This would not be expected to substantially 
change the parameter estimates obtained but certainly would increase the uncertainty around them. Our 
inability to create robust uncertainty intervals around our estimates is the primary weakness of this piece of 
work. Unfortunately the lipid analyses were even less rigorous, with so few studies, confidence in the meta-
analysis is limited. There is much potential for further work in this area to generate reliable regression analyses 
for use in the field. 
On a more positive note, the association between results based on venous and DBS samples appeared to be 
consistent at the levels of HbA1c at which diabetes mellitus is diagnosed (HbA1c > 6.5%92).  This implies that 
DBS samples could already be used for determining the presence or absence of diabetes with reasonable 
certainty, although measures of the extent to which blood glucose is controlled amongst those with diabetes 
would be less reliable.  
Most of the studies reported some information about DBS sample preparation, transport and storage but the 
data were provided in diverse formats and were substantively incomplete.  While it appears likely that DBS 
samples are stable for adequate periods of time this is an area that requires systematic evaluation and the 
development of standardised recommendations prior to widespread roll out of the methodology. 
The establishment of World Health Organization ‘’25 by 25’’ target for the prevention of non-communicable 
diseases 93 has added urgency to the need for data about the metabolic determinants of cardiovascular risk.  
With more than three quarters of all chronic disease now occurring in developing country settings, the 
introduction of low cost research techniques that will provide the data required to inform government 
decision making is a priority 94.  DBS sample collection methods appear to have great potential for the 
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evaluation of cardiometabolic risk factors at the population level 65, 69, 85 enabling data collection at scale in 
areas previously unstudied 71. There remain, however, important advances to be made in defining standard 
methodologies and adjustments before the DBS sampling method is confirmed as a sound proxy for traditional 
venepuncture samples for these types of blood analytes. 
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TABLE 3-1. CHARACTERISTICS AND FINDINGS OF INCLUDED STUDIES 
 
N 
 
Diabetes 
 
Population 
source Mean (SD) of DBS values 
Regression equation 
 
HbA1c     
 Anjali 200775 78 Yes - 9.45 (±1.86) DBS = 0.95V + 1.4 
Buxton 200995 115 - Hospital - DBS = 0.85V + 0.81 
Egier 201165 85 - - - DBS = 0.933V + 0.4 
Fokkema 200978* 93 - Community - DBS = 1.006V - 0.092 
Fokkema 200978* 88 - Community - DBS = 0.994V + 0.057 
Fokkema. 200978* 73 - Community - DBS = 0.987V - 0.011 
Gay 199079 58 Yes Community 10.8 (±2) DBS = 0.8V + 1.8 
Jeppsson 199677 41 - - 7.49 DBS = 0.99V + 0.16 
Jones 201066* 73 - - 6.74 DBS = 0.984V + 0.189 
Jones 201066* 40 - - 8 DBS = 0.998V - 0.204 
Lacher et al 201380  386 - Community 5.92 (±1.2) DBS = 0.94V + 0.37 
Lakshmy 200981 30 - Community 5.94 (±1.58) DBS = 0.9886V + 0.0018 
Little 198684 78 Yes/No - 10.2 DBS = 1.09V + 2.17 
Lomeo 200885 97 - - - DBS = 0.877V + 1.09 
Tabatabaei-Malazy 201187* 33 Yes Community 8.8 (±1.6) DBS = 1.20V - 0.635 
Tabatabaei-Malazy 201187* 33 Yes - 8.9 (±1.7) DBS = 1.25V - 1.09 
Wikblad 199886 145 Yes - - DBS = 1.03V - 0.405 
Triglycerides     
 Lakshmy 201082* 85 - Community 1.6 (±0.6) DBS = 1.028V - 0.1690 
Lakshmy 201283* 613 - Community 1.16 to 1.87 (±0.45 to 0.79) DBS = 0.9549V + 0.1875 
Quraishi 200689 75 - Community 1.297 (±0.53) DBS = 0.88V + 0.13 
Total Cholesterol   -  
 Lacher 201380 395 - Community 3.76 (±0.87) DBS = 0.52V + 1.08 
Lakshmy 201082* 85 - Community 5 (±1) DBS = 0.727V + 1.170 
Lakshmy 201283* 613 - Community - DBS = 0.7779V + 1.1943 
HDL      
Lacher 201380 395  Community 1.41 (±0.42) DBS = 0.7V + 0.46 
*SOME STUDIES PROVIDED MULTIPLE ESTIMATES AND ARE REPEATED IN THE TABLE. SD=STANDARD DEVIATION, DBS=DRIED BLOOD SPOT, V=VENOUS 
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TABLE 3-2. METHODS OF SAMPLE ANALYSIS IN THE DIFFERENT STUDIES  AC= AFFINITY CHROMATOGRAPHY, TII=TURBIDIMETRIC INHIBITION IMMUNOASSAY, ION= ION EXCHANGE 
CHROMATOGRAPHY, HPLC=HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, HR=HAEMOLYSING REAGENT, COL=COLORIMETRY. SOME STUDIES INVOLVED MULTIPLE SAMPLES AND ARE 
REPEATED IN THE TABLE
 
Dried blood spot data collection details Assay methods 
  
Drying Transportation Extraction method DBS Venous 
HbA1c    
  Anjali 200775 - - Anti-HbA1c antibody. TII TII 
Buxton 200995 - Special shipping Roche HbA1c HR. TII HPLC 
Egier 201165 - - Extraction buffer HPLC HPLC 
Fokkema 200978* -  - HR TII TII 
Fokkema 200978* - Routine mail HR TII TII 
Fokkema. 200978* - -  TII TII 
Gay 199079 Yes Routine mail - AC Ion 
Jeppsson 199677 - Routine mail Triton X-100 buffer HPLC HPLC 
Jones 201066* Yes - HR and anti-HbA1c antibody. TII TII 
Jones 201066* Yes Special shipping HR and anti-HbA1c antibody. TII HPLC 
Lacher 201380 Yes Packed in dry ice Extraction buffer HPLC HPLC 
Lakshmy 200981 Yes - Anti-HbA1c antibody TII/HPLC TII 
Little 198684 Yes - Water AC AC 
Lomeo 200885 - - HR HPLC HPLC 
Tabatabaei-Malazy 201187* Yes - - TII TII 
Tabatabaei-Malazy 201187* Yes - - TII TII 
Wikblad 199886 - Routine mail Phosphate-citrate buffer HPLC TII 
Triglycerides    
  Lakshmy 201082* - Packed in ice  Methanol  Col.  Col. 
Lakshmy 201283* Yes Packed in ice Methanol  Col. Col. 
Quraishi 200689 Yes - Methanol  Col. Col. 
Total Cholesterol    
  Lacher 201380 Yes Packed in dry ice Deionized water Col. Col. 
Lakshmy 201082* - Packed in ice  Methanol  Col. Col. 
Lakshmy 201283* Yes Packed in ice  Methanol  Col. Col. 
HDL      
Lacher 201380 Yes Packed in dry ice Deionized water Col. Col. 
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FIGURE 3-3. THE MEAN HBA1C VALUES FROM THE STUDIES ARE COMPARED WITH THE REGRESSION INTERCEPT THE STUDY 
GENERATED. THE MARKER SIZE IS PROPORTIONAL TO STUDY SIZE. 
 
 
 
FIGURE 3-4. THE MEAN HBA1C VALUES FROM THE STUDIES ARE COMPARED WITH THE REGRESSION COEFFICIENT THE 
STUDY GENERATED. THE MARKER SIZE IS PROPORTIONAL TO STUDY SIZE.  
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FIGURE 3-6. FUNNEL PLOT OF THE HBA1C REGRESSION COEFFICIENTS 
FIGURE 3-5. FUNNEL PLOT OF THE HBA1C REGRESSION INTERCEPTS. 
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Chapter 4. Prevalence of Dysglycaemia in Rural Andhra Pradesh – 2005, 
2010 and 2014 
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and Bruce C Neal. Submitted to ‘Journal of Diabetes’. 
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multiple edits of the publication. Eshan Affan also formed the main body of the text. 
Andhra Pradesh Rural Health Initiative – This was a previously conducted survey with results published earlier 
by Clara Chow and Bruce Neal. Eshan Affan restructured the collected data and represented specific 
subsections to make a valid comparison with the other two surveys.  
Gates Grand Challenge #13 Survey – Eshan Affan managed the data after collection. Developed and 
implemented the method of analysing the particular survey structure with Devarsetty Praveen. Eshan Affan 
conducted the analysis of the results and presented the diabetes and blood lipid prevalence. Jason Wu 
provided guidance on the methodology and statistical analysis. 
SMARTHealth survey – David Pereis, Anushka Patel and Devarsetty Praveen were responsible for the data 
collection. Eshan Affan managed the diabetes data after collection, conducted the analysis and presented the 
diabetes prevalence results. Anushka Patel, Clara Chow, David Pereis and Jason Wu provided critical analysis of 
the methodology of the comparative study. 
INTRODUCTION 
Although infectious diseases remain a significant cause of morbidity and mortality in developing countries,96 
non-communicable diseases are increasingly prevalent and now represent about half the burden of disease in 
South Asia.10 India is developing rapidly and lifestyle changes are occurring throughout much of the country, 
with a projected 150% increase in diabetes mellitus prevalence to more than 80 million by 2030.97  These 
estimates are, however, based on limited data and have significant uncertainty about them.  There are few 
studies in India that have made repeat assessments of diabetes prevalence in the same population, using 
similar methods and this is particularly true in rural areas where some 70% of the population lives.13, 46  The 
available data suggest a substantial rise in diabetes prevalence in rural areas over the last few decades with 
one large survey done in 1991 reporting a rate of just 0.4% compared to a 2005 estimate of 13.2% in a study 
done in rural Andhra Pradesh.13, 14, 46, 98, 99 In that 2005 Andhra Pradesh Rural Health Initiative (APRHI) study a 
further 15.5% of the population were classified as having impaired fasting glucose such that 28.7% of the 
population had some form of dysglycaemia. In 2010 the same Godavari area of Andhra Pradesh was re-
surveyed as part of the Gates Grand Challenge 13 (GC13)100 health metrics evaluation which included an 
assessment of diabetes prevalence.  Most recently a further survey of the same population was done as a part 
of the Systematic Medical Appraisal Referral and Treatment Health (SMARThealth) initiative.101 SMARThealth is 
a project utilising low-cost smartphone technologies to provide high quality health care to rural India. In this 
paper we report and compare the estimated prevalence of dysglycaemia in the West Godavari district of rural 
Andhra Pradesh in 2005, 2010, and 2014. 
METHODS 
The APRHI project received approval from the ethics committees of the CARE Hospital, Hyderabad in India and 
the University of Sydney in Australia, the GC13 project from the ethics committee of the Gandhi Medical 
College and Hospital and the University of Sydney and the SMARThealth initiative from the ethics committees 
of the Centre for Chronic Disease Control, New Delhi and the University of Sydney in Australia. In every case 
survey participants were provided written and/or oral information about the respective study in their local 
language and written informed consent was obtained prior to participation. 
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Survey Characteristics 
The 2005 APRHI survey - included 4535 adults aged 30 to 100 from 20 villages (total population 75 089) in the 
East and West Godavari regions of Andhra Pradesh.  The 20 villages were selected to be representative of the 
area and used stratified random sampling. The population was divided into 8 groups on the basis of age (30-
39, 40-49, 50-59, 60+) and sex with individuals sampled at random within these strata. This strategy was used 
to ensure similarly precise age and sex specific estimates with post-stratification weights applied to enable 
estimation of overall population means and prevalences. Each individual had a brief physical examination, 
completed a questionnaire, and a fasting plasma glucose (FPG) measurement made on a fingerprick blood 
glucose sample. The detailed methods of the APRHI study have been reported previously.13, 14, 46 
GC13 survey - included 4024 adults aged 15 to 94 from 14 villages (total population 55 151) also in the West 
Godavari region of Andhra Pradesh.  The 14 villages were selected to be representative of the area with 
stratified clustered sampling of individuals from the selected villages. The initial stratification was by village 
and then the primary sampling units in each village were randomly selected households from which an 
individual was randomly selected for inclusion and completion of the initial questionnaire stage.  A further 
round of stratified random sampling of these individuals identified a subset from whom a dried blood spot 
(DBS) was collected for assessment of haemoglobin A1c (HbA1c).  This sampling was done with predetermined 
post-stratification sampling weights to achieve similar sample sizes in each age and sex stratum of the 
population with a total of 851 DBS samples collected (Figure 4-2). The villages included in GC13 were from the 
same region as APRHI and 4 of the villages were common to both surveys. 
The 2014 SMARThealth survey - included 62 254 adults aged 40 to 85 years from 54 villages (total population 
209 868) in the same West Godavari region of Andhra Pradesh. A total of 18 Primary Health Care Centres 
(PHCs), broadly representative of the West Godavari District of Andhra Pradesh were selected. From the 
region serviced by each PHC, three villages were randomly selected. A census list comprising age and sex of all 
residents was first enumerated from the 54 villages and each household was then visited. All eligible persons 
of age 40 years and above were identified and invited for an interview and clinical assessment. 62 194 
participants had capillary blood glucose measurements made, with capture of information on fasting state at 
the time of measurement.  
Data collection, blood sampling and analysis methods 
2005 APRHI - Data collection was during February and March 2005 by trained staff using a structured 
questionnaire. Participants were asked about a previous diagnosis of diabetes by a medical practitioner or if 
they were currently taking an oral hypoglycaemic and/or insulin. Weight and height were measured with 
participants wearing light clothing and no shoes. A fasting finger-prick blood glucose measurement was sought 
for all participants using B-Braun (Germany) U.S.V. meters which were calibrated to give venous plasma 
glucose equivalents. Diabetes was classified as self-reported diabetes or a FPG ≥ 7 mM and impaired fasting 
glucose was designated as prediabetes within the range 5.6 mM < FPG ≤ 6.9 mM.43 For the very small 
proportion who were not fasting at the time of blood sampling, diabetes was classified as self-reported 
diabetes or a random plasma glucose (RPG) ≥ 11.1 mM and prediabetes was defined by the range 7.8 mM < 
RPG ≤11 mM.43  
2010 GC13 - Data collection was done from July 2009 to February 2010 using laptops to guide the interviews 
and enable real-time data entry and data checking.  Participants were asked whether they had a diagnosis of 
diabetes by a health practitioner and if they were currently taking ‘diabetic pills’. Weight and height were 
measured with shoes and heavy outer clothing removed.  Blood collection was by a finger prick with the 
sample collected onto filter paper and air dried for two to three hours. Samples were then placed into a plastic 
bag and stored at 4oC for a maximum of 10 days before being sent by courier to Hyderabad for longer-term 
storage. DBS samples were analysed at the Nizams Institute for Medical Sciences in Hyderabad, Andhra 
Pradesh. Analysis was done by immunoturbidimetry using the Randox latex agglutination inhibition assay, 
Randox Laboratories Ltd. The DBS findings were minimally adjusted using a regression equation that defines 
the association between immunoturbidimetric analyses of HbA1c DBS samples and fasting venous samples 
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tested using handheld glucose monitors.102 Diabetes was defined as self-reported diabetes or HbA1c > 6.5% 
and prediabetes as 5.7% < HbA1c ≤ 6.4%.43 
2014 SMARThealth - Data collection was done between February and May 2014.  Participants were also asked 
about previously diagnosed diabetes. Capillary blood collected using the finger-prick method from participants 
in either a fasted or non-fasted state was assayed with the Abbott Freestyle Optium glucometer.  Whether or 
not the participant was fasting at the time of sampling was recorded and the same diagnostic standards as 
APRHI were used for the classification of glycaemic status based upon FPG or RPG. There was no data on oral 
hypoglycaemic usage in 2014, although this is not expected to change the diabetes prevalence significantly as 
previously known diabetes was asked for. 
In all three studies participants on oral hypoglycaemics, insulin or with a self-reported history of diabetes were 
classified as having diabetes and could not be classified as having pre-diabetes. The aggregate of diabetes and 
prediabetes defined dysglycaemia. 
Statistical Analysis 
Analyses were restricted to the 40-85 year age group common to all three surveys. Estimates of the prevalence 
of dysglycaemia were made for the 20 villages included in APRHI and for the 14 villages included in GC13 by 
weighting the data obtained from the survey participants.  The weighting method used to obtain summary 
estimates for the 20 and 14 villages, respectively, varied between the two surveys reflecting the different 
approaches taken to sampling. For APRHI, which used simple stratified random sampling, post-stratification 
weighting was employed using data from a population census done by the Byrraju Foundation in 2004.  For 
GC13 the stratified cluster sampling used to identify the households and the individual within each for 
inclusion, followed by secondary stratified sampling of the included individuals for measurement of HbA1c, 
required a more complex weighting methodology based upon the product of the probability weights and the 
post-stratification weights (Appendix 1).45 These weighting strategies provided appropriate age and sex 
standardised estimates as well as minimised sampling bias. The SMARThealth data required no weights since it 
was a full survey of the entire population with a substantially complete response of individuals in the 54 
villages included. Four villages were common to APRHI and GC13, two were common to APRHI and 
SMARThealth, and two were common to GC13 and SMARThealth. None were included in all three studies. 
The primary analyses based upon directly comparable assessment methods (using only participants with FPG 
samples) were made using data from 2005 and 2014. Secondary analyses included all participants with data 
aged 40-85 years in all three studies. The secondary analyses were done to explore the potential impact on the 
prevalence estimates of the different measurement methods upon which definitions of dysglycaemia, diabetes 
and prediabetes could be based. The statistical software package STATA 11.0 (StataCorp, College Station, TX, 
USA) was used for all analyses. The ‘svy’ command which supports the inclusion of survey weights was the 
basis of most analyses. Continuous variables are presented as mean and 95% confidence intervals and 
compared using the unpaired Student’s t-test or analysis of variance (ANOVA). Differences between 
proportions were tested for significance using the chi-squared test for homogeneity. 
RESULTS 
The primary analyses of dysglycaemia were based upon 3243 individuals from APRHI and 749 individuals from 
SMARThealth for whom fasting plasma glucose samples were available. The primary difference in population 
characteristics across the two surveys (Table 4-1) was a more than one unit rise in mean BMI driven by an 
approximate 1.7kg rise in mean weight.  For the secondary analyses there were 3333 individuals aged 40 to 85 
included from the APRHI study in 2005 with a response rate of 81%; 2200 individuals included from the GC13 
survey done in 2010 with a response rate of 82%; and 62 254 participants included from the SMARThealth  
survey in 2014 with a response rate of 84%.  The characteristics of the participants included in the secondary 
analyses were comparable to the characteristics of the populations used in the primary analyses with 
significant increases observed between 2005, 2010, and 2014 for both BMI (p<0.001) and weight (p<0.001) 
(Table 4-1). 
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In the primary analyses done for 2005 and 2014 amongst participants with fasting plasma glucose samples, the 
estimated prevalence of dysglycaemia was 53.7% (51.8 - 55.7, 95% CI) in 2005 and 62.0% (58.5 - 65.4, 95% CI) 
in 2014 (p<0.001) (Figure 4-1a).  The corresponding prevalence estimates for diabetes were 17.4% (15.9 - 18.9, 
95% CI) and 29.9% (26·6 - 33·2, 95% CI) (p<0.001) and for prediabetes were 36·3% (34.4 - 38.2, 95% CI) and 
32.0% (28.7 - 35.4, 95% CI) (p=0.088). The proportions aware of their diabetes in each year were 49% and 31%. 
The mean body mass index (BMI) increased from 2005 to 2014 was 1.3 kg/m2 in females (rising from 22.6 
kg/m2 to 23.9 kg/m2; p=0.002) and 0.8 kg/m2 in males (21.8 kg/m2 rising to 22.6 kg/m2; p=0.002). The increase 
in dysglycaemia over this period was entirely in women and driven by an approximate doubling in the 
prevalence of diabetes. 
For the secondary analyses the estimated prevalence of dysglycaemia was 53.9% (52.0 - 55.9, 95% CI) in 2005, 
50.5% (46.1 - 54.9, 95% CI) in 2010, and 41.3% (40.9 - 41.7, 95% CI) in 2014 with the data suggesting a decline 
across the three time points (p<0.001) (Figure 4-1b).  The corresponding prevalence estimates for diabetes 
were 17.8% (16.3 - 19.3, 95% CI), 33.6% (29.4 - 37.9, 95% CI) and 18.1% (17.8 - 18.4, 95% CI) with the 2010 
data based upon HbA1c assays providing a markedly higher estimate of diabetes for 2010 (p<0·001). For 
prediabetes the estimates of prevalence were 36.1% (34.3 - 38.0, 95% CI) in 2005, 17.2% (13.8 - 20.7, 95% CI) 
in 2010 and 23.2% (22.8 - 23.5, 95% CI) in 2014, again with substantial variation across years (p<0.001). The 
proportions of the population reporting use of an oral hypoglycaemic were 5.82% (4.94 - 6.71, 95% CI) in 2005 
and 8.21% (6.89 - 9.53, 95% CI) in 2010.  
DISCUSSION 
These research findings leave little doubt that the prevalence of dysglycaemia is very high in this rural Indian 
population and indicate that the rates of both diabetes and pre-diabetes have been elevated for at least a 
decade.  This bodes ill for the cardiovascular health of this community and the adverse effects are already 
apparent in recent measures of vascular disease burden.46  More concerning is the possibility that similarly 
high, but as yet undocumented, rates of diabetes may be present in other parts of rural India.  This raises the 
prospect that current projections for diabetes and diabetes-related disease burden in India10 may be 
significant under-estimates. 
While the large magnitude of the diabetes problem in this population is clear from our data, whether it is 
improving or worsening, is less immediately apparent.  The primary analyses based upon the subset with 
assessments made on directly comparable fasting blood samples suggest an increase in dysglycaemia from 
2005 through 2014 which is consistent with the increase in BMI and weight observed over the same time 
period.  By contrast, our secondary analyses that used all the data available suggest a decline in rates of 
dysglycaemia over the same period.  These secondary estimates employed recognised,43 but different, 
methods of assessment at each time point and this appears to have confused the picture in terms of 
estimating change.  It is well known that estimates of dysglycaemia prevalence based upon assays of RPG 
levels can be affected by factors such as the average time between sampling and the last meal.103  The use of 
prevalence assessments in 2010 based upon assays of HbA1c introduced further challenges to the 
interpretation of the data.  It seems likely that the dysglycaemia prevalence rates based on HbA1c were a slight 
underestimate compared to what would have been obtained if fasting venous samples had been used, but the 
main issue arose with the use of HbA1c values to differentiate between diagnoses of diabetes and prediabetes.  
The very high rates of diabetes inferred for 2010 suggest that the recommended HbA1c cut point for 
differentiating between diabetes and pre-diabetes43 is unsuitable for this population.  Of note, the use of DBS 
samples for HbA1c assay is well established and robust, and while a minor adjustment was made using a 
published regression equation,102 the impact of that adjustment on the primary results was minimal. 
We believe that biases consequent upon the use of different assessment methods are the most likely 
explanation for the difference between the findings of the primary and secondary analyses we did.  Restricting 
the primary comparison to the subset of participants assessed with directly comparable techniques should 
have provided a good approximation of truth by minimising the risk of confounding.  While the quantity of 
participants upon which the primary analyses were based is much lesser than for the secondary analyses, the 
primary comparison still included fairly large numbers and provided reasonably precise estimates.  
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Furthermore, the characteristics of this subset were not markedly different from either the full 2014 
SMARThealth sample or the 2005 APRHI sample (Tables 4-3 and 4-4) so the primary analysis findings should be 
generalizable to the broader population.  Internal consistency in the findings for men and women within the 
primary data provide additional reassurance of the likely quality of these analyses - the increase in diabetes 
was observed in the female population for which a larger increase in body mass index was also observed. 
The problems with estimating the prevalence of diabetes, pre-diabetes and dysglycaemia in this study raise 
important questions about the comparability of accepted methods for estimating diabetes prevalence from 
different types of samples using different assays,102, 104 even when there are population-specific 
recommendations for each.105  A series of prior reports have identified similar challenges106, 107, 105, 108 although 
the extent of the problem we observed has not previously been identified.28, 109  The criteria used for the 
diagnosis of diabetes, pre-diabetes and dysglycaemia based upon different assay techniques in Indian 
populations are inconsistent and further work is required to clarify the cut points at which the correct 
prevalence estimates would be achieved.  
Our conclusion of a high, and likely increasing, prevalence of dysglycaemia would not be unique to this rural 
Indian community – an almost three-fold increase (2.4% to 6.4%) in diabetes prevalence was reported for the 
14 year period from 1989 to 2003 in neighbouring rural Tamil Nadu110 with a further escalation of prevalence 
to close to four times (9.2%) the 1989 value reported from a survey done in the same population in 2006.32 
The rates of self-awareness of diabetes observed in our study compare favourably to the 31% reported in 
urban Indian settings.111 An elevated level of NGO activity in these villages in the period leading up to the initial 
APHRI survey and a series of subsequent initiatives in the area are likely to be a part of the explanation for the 
relatively high awareness.112 
Diabetes and prediabetes are responsible for considerable morbidity and mortality caused by macro-vascular 
and micro-vascular disease complications.43, 105, 108 Progressive urbanisation of the Indian population,43, 113 
increases in life expectancy114 and unhealthy lifestyles are likely to further compound the consequences of 
dysglycaemia,115 as is a likely genetic predisposition to type 2 diabetes and serious complications amongst 
South Asians.93, 115  Our data shine a further spotlight on the huge issue of diabetes in the Indian population.  
Regardless of the challenges in interpreting the details of the findings reported here, it is clear that diabetes is, 
and will remain, a major health challenge for the country.  Novel initiatives such as the SMARThealth project 
seeking to identify simple, low costs and scalable solutions to chronic disease management in rural India are 
urgently required.  Robust evaluation of these types of initiatives will be vital and our findings highlight the 
need for the use of standardised methods to achieve this. 
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Table 4-1. Characteristics of surveyed populations in 2005, 2010, and 2014  
Comparisons were made using ANOVA for continuous variables and a chi-squared test for homogenous 
proportions for categorical variables. Unpaired Student’s t-test for continuous variables used for comparing 
when only two studies included. 
Values are weighted estimates reflecting the mean population values for the 20 villages surveyed in APRHI in 
2005, the 14 villages surveyed in GC13 in 2010 and 54 villages from SMARThealth 2014. 
‘-‘ indicates data not collected. 
 
 2005 
% (95%CI) 
2010 
% (95%CI) 
2014 
% (95%CI) 
P- 
Value 
PARTICIPANTS INCLUDED IN PRIMARY ANALYSES BASED UPON THOSE WITH FASTING SAMPLES 
 
Age (years) 54·1 (53·7-54·6) 
 
 55·0 (54·2-55·8) 0·112 
Males (%) 50·6 (48·6-52·6)  45·7 (42·1-49·2) 0·052 
Weight (kg) 54·4 (53·9-54·9)  56·1 (54·1-58·1) 0·019 
Height (cm) 156·4 (156·0-156·7) 
 
 154·6 (153·3-156·0) 0·050 
BMI (kg/m2) 22·2 (22·0-22·3)  23·3 (22·5-24·0) <0·001 
Formal Schooling (%) 48·4 (46·5-50·4)  50·9 (47·3-54·5) 0·477 
Smokers (%) 28·1 (26·3-29·9)  30·3 (27·0-33·6) 0·506 
Previous MI (%) 1·73 (1·24-2·22) 
 
 3·47 (2·16-4·79) <0·001 
Previous Stroke (%) 2·36 (1·81-2·90)  2·54 (1·41-3·67) 0·966 
PARTICIPANTS INCLUDED IN SECONDARY ANALYSES OF ALL SURVEYED 
Age (years) 54·1 (53·6-54·5) 
 
55·7 (52·2-56·3) 
 
54·1 (54·0-54·2) 0·005 
Males (%) 50·9 (49·0-52·9) 
 
48·5 (46·2-50·8) 46·8 (46·4-47·2) <0·001 
Weight (kg) 54·4 (53·9-54·9) 
 
55·9 (55·4-56·5) 58·8 (58·6-59·1) <0·001 
Height (cm) 156·4 (156·1-156·8) 
 
156·5 (156·1-156·9) 155·2 (155·0-155·4) 0·011 
BMI (kg/m2) 22·2 (22·0-22·3) 
 
22·8 (22·6-23·0) 
 
24·3 (24·2-24·4) <0·001 
Formal Schooling (%) 48·8 (46·9-50·8) 
 
74·9 (72·9-76·9) 
 
55·9 (55·5-56·3) <0·001 
Smokers (%) 28·6 (26·8-30·3 
 
28·0 (25·9-30·1) 
 
27·5 (27·2-27·9) 0·391 
Previous MI (%) 1·70 (1·23-2·18) 
 
3·43 (2·59-4·27 
 
2·29 (2·17-2·41) 0·001 
Previous Stroke (%) 2·37 (1·83-2·92) 2·16 (1·44-2·88) 
 
1·76 (1·65-1·86) 0·032 
Previous Angina (%) 5·03 (4·19-5·87) 1·91 (1·29-2·53) - <0·001 
 
 Page 34 of 93 
 
Table 4-2. Prevalence of diabetes and prediabetes in 2005, 2010, and 2014 and differences by 
age and by sex amongst all aged 40 to 85 
Comparisons were made using Chi-Squared tests for homogeneity. 
 
 2005 
% (95%CI) 
2010 
% (95%CI) 
2014 
% (95%CI) 
P- Value 
 
PRIMARY ANALYSES BASED UPON THOSE WITH DIRECTLY COMPARABLE FASTING SAMPLES 
Dysglycaemia (diabetes or prediabetes) 
Men 55·1 (52·2-57·9)  52·8 (48·0-57·7) 0·606 
Women 52·3 (49·6-55·1)  72·8 (68·1-77·5) <0·001 
Age (yrs)     
 40-49 50·5 (47·1-54·0)  55·2 (49·4-60·9) 0·345 
 50-59 56·0 (52·4-59·6)  62·3 (55·6-69·1) 0·290 
 60+ 55·7 (52·6-58·8)  69·2 (63·6-74·9) <0·001 
Diabetes     
Men 18·9 (16·7-21·0)  23·6 (19·5-27·7) 0·115 
Women 15·9 (13·9-17·9)  37·4 (32·2-42·6) <0·001 
Age (yrs)     
 40-49 13·4 (11·1-15·8)  23·4 (18·6-28·3) <0·001 
 50-59 19·0 (16·2-21·8)  33·7 (27·1-40·3) <0·001 
 60 + 20·7 (18·1-23·2)  34·2 (28·4-40·0) <0·001 
Pre-diabetes     
Men 36·3 (33·6-39·0)  29·2 (24·8-33·7) 0·028 
Women 36·4 (33·8-39·1)  35·4 (30·3-40·5) 0·933 
Age (yrs)     
 40-49 37·1 (33·8-40·4)  31·7 (26·3-37·1) 0·253 
 50-59 37·0 (33·5-40·5)  28·6 (22·3-35·0) 0·075 
 60 + 35·0 (32·1-38·0)  35·0 (29·2-40·8) 0·999 
SECONDARY ANALYSES BASED UPON ALL SURVEYED 
Dysglycaemia (diabetes or prediabetes) 
Men 55·3 (52·6-58·1) 56·5 (50·4-62·7) 40·3 (39·7-40·9) <0·001 
Women 52·4 (49·7-55·2) 43·0 (36·6-49·3) 42·1 (41·6-42·6) <0·001 
Age (yrs)     
 40-49 50·5 (47·1-54·0) 48·5 (40·8-56·2) 33·6 (33·0-34·2) <0·001 
 50-59 55·7 (52·1-59·3) 50·7 (41·4-59·9) 45·1 (44·4-45·9) <0·001 
 60+ 55·4 (52·4-58·5) 53·0 (46·9-59·1) 47·9 (47·3-48·6) 0·013 
Diabetes     
Men 19·3 (17·2 to 21·5) 37·0 (31·0 to 43·0) 17·8 (17·4-18·3) <0·001 
Women 16·2 (14·2 to 18·2) 29·6 (23·6 to 35·2) 18·3 (17·9-18·8) 0·001 
Age (yrs)     
 40-49 13·5 (11·0 to 16·0) 27·7 (20·7 to 34·7) 12·7 (12·3-13·1) <0·001 
 50-59 19·1 (16·1 to 22·1) 34·2 (25·2 to 43·2) 21·8 (21·2-22·4) 0·003 
 60 + 20·5 (17·8 to 23·2) 41·0 (34·9 to 47·1) 22·0 (21·4-22·5) <0·001 
Pre-diabetes     
Men 36·0 (33·4-38·7) 19·8 (14·7-24·8) 22·5 (22·0-23·0) <0·001 
Women 36·2 (33·6-38·9) 14·1 (9·46-18·6) 23·8 (23·3-24·2) <0·001 
Age (yrs)     
 40-49 37·0 (33·7 to 40·3) 20·8 (14·5 to 27·1) 20·9 (20·4-21·4) <0·001 
 50-59 36·6 (33·2 to 40·1) 17·2 (10·2 to 24·2) 23·3 (22·7-24·0) <0·001 
 60 + 34·9 (32·0 to 37·9) 12·5 (8·54 to 16·5) 25·9 (25·3-26·6) <0·001 
 Page 35 of 93 
 
Figure 4-1. Prevalence of diabetes and pre-diabetes in 2005, 2010, and 2014 
a) Fasting participants only (primary analyses) 
 
 
 
b) All adults regardless of assessment method (secondary analyses) 
 
‘Undiagnosed’ is equivalent to previously unknown cases of diabetes, diagnosed only during this study.  
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Figure 4-2. Survey structures for APRHI and GC13 
 
GC13  
𝑖 = 𝑜𝑛𝑒 𝑜𝑓 14 𝑠𝑡𝑟𝑎𝑡𝑎 (𝑣𝑖𝑙𝑙𝑎𝑔𝑒𝑠) 
𝑀𝑖 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 (ℎ𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑𝑠) 𝑖𝑛 𝑡ℎ𝑒 𝑖 − 𝑡ℎ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
𝑚𝑖 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝑠𝑢𝑟𝑣𝑒𝑦𝑒𝑑 𝑖𝑛 𝑖 − 𝑡ℎ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
𝑗 = 𝑎 𝑝𝑎𝑟𝑡𝑖𝑐𝑢𝑙𝑎𝑟 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 
𝑁𝑖𝑗  = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑎𝑔𝑒𝑑 𝑎𝑏𝑜𝑣𝑒 15 𝑖𝑛 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑗 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖  
𝑁𝑖  = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑎𝑔𝑒𝑑 𝑎𝑏𝑜𝑣𝑒 15 𝑖𝑛 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖 
𝑛𝑖𝑗  = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑠𝑢𝑟𝑣𝑒𝑦𝑒𝑑 𝑖𝑛 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑗 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖 
𝑛𝑖  = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑠𝑢𝑟𝑣𝑒𝑦𝑒𝑑 𝑖𝑛 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖 
𝑁𝑖𝑘 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑎𝑔𝑒𝑑 𝑎𝑏𝑜𝑣𝑒 15 𝑖𝑛 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖 𝑖𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑔𝑒 𝑠𝑒𝑥⁄ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑘 
𝑛𝑖𝑘  = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑠𝑢𝑟𝑣𝑒𝑦𝑒𝑑 𝑖𝑛 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖 𝑖𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑔𝑒 𝑠𝑒𝑥⁄ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑘 
Where the 10 standard strata: 15-29, 30-39, 40-49, 50-59, 60+ for both males and females. 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑝𝑤𝑖𝑗 =  
1
𝑃(𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑛𝑔 ℎ𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 𝑗) × 𝑃(𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑛𝑔 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙)
 
=  
1
𝑚𝑖
𝑀𝑖
×
1
𝑁𝑖𝑗
  
 𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒, 𝑝𝑤𝑖𝑗 =  
𝑀𝑖𝑁𝑖𝑗
𝑚𝑖
 
𝑃𝑜𝑠𝑡 − 𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑠𝑖𝑘 =  
𝑁𝑖𝑘
𝑁𝑖
𝑛𝑖𝑘
𝑛𝑖  
 
𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒 𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑤𝑖𝑗𝑘 =  𝑝𝑤𝑖𝑗 × 𝑠𝑖𝑘  
 
APRHI 
𝑁𝑘 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒   𝑖𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑔𝑒 𝑠𝑒𝑥⁄ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑘 
𝑛𝑘  = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑠𝑢𝑟𝑣𝑒𝑦𝑒𝑑 𝑖𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑔𝑒 𝑠𝑒𝑥⁄ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑘 
Where the 8 standard strata: 30-39, 40-49, 50-59, 60+ for both males and females. 
 
𝑃𝑜𝑠𝑡 − 𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑠𝑘 =  
𝑁𝑘
𝑛𝑘
 
Detailed weighting structure of the studies. 
 
 
 
 
 
 Page 37 of 93 
 
Table 4-3. Characteristics of surveyed population in 2014 amongst all and fasting only aged 40 
to 85 years of age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparisons were made using Unpaired Student’s t-test for continuous variables and a chi-squared test for 
homogenous proportions for categorical variables. 
Values are weighted estimates reflecting the mean population values for the 54 villages from SMARThealth 
2014. 
  
 2014 Full Sample 
% (95%CI) 
n=62,254 
2014 Fasting 
% (95%CI)  
n=749 
P- Value 
Age (years) 54·1 (54·0-54·2) 55·0 (54·2-55·8) 0·860 
Males (%) 46·8 (46·4-47·2) 45·7 (42·1-49·2) 0·841 
Weight (kg) 58·8 (58·6-59·1) 56·1 (54·1-58·1) 0·054 
Height (cm) 155·2 (155·0-155·4) 154·6 (153·3-156·0) 0·520 
BMI (kg/m2) 24·3 (24·2-24·4) 23·3 (22·5-24·0) 0·031 
Formal Schooling (%) 55·9 (55·5-56·3) 50·9 (47·3-54·5) 0·024 
Smokers (%) 27·5 (27·2-27·9) 30·3 (27·0-33·6) 0·224 
Previous MI (%) 2·29 (2·17-2·41) 3·47 (2·16-4·79) 0·085 
Previous Stroke (%) 1·76 (1·65-1·86) 2·54 (1·41-3·67) 0·240 
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Table 4-4. Characteristics of surveyed population in 2005 amongst all and fasting only aged 40 
to 85 years of age 
 
Comparisons were made using Unpaired Student’s t-test for continuous variables and a chi-squared test for 
homogenous proportions for categorical variables. 
Values are weighted estimates reflecting the mean population values for the 20 villages from APRHI 2005. 
 
 
 
 
 
 
 
 
 
 2005 Full Sample 
% (95%CI) 
2005 Fasting 
% (95%CI) 
P- Value 
Age (years) 54·1 (53·6-54·5) 
 
54·1 (53·7-54·6) 
 
0.999 
Males (%) 50·9 (49·0-52·9) 
 
50·6 (48·6-52·6) 0.970 
Weight (kg) 54·4 (53·9-54·9) 
 
54·4 (53·9-54·9) 0.999 
Height (cm) 156·4 (156·1-156·8) 
 
156·4 (156·0-156·7) 
 
0.999 
BMI (kg/m2) 22·2 (22·0-22·3) 
 
22·2 (22·0-22·3) 0.999 
Formal Schooling (%) 48·8 (46·9-50·8) 
 
48·4 (46·5-50·4) 0.942 
Smokers (%) 28·6 (26·8-30·3 
 
28·1 (26·3-29·9) 0.909 
Previous MI (%) 1·70 (1·23-2·18) 
 
1·73 (1·24-2·22) 
 
0.999 
Previous Stroke (%) 2·37 (1·83-2·92) 2·36 (1·81-2·90) 0.999 
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Chapter 5. Blood Lipids in Rural Andhra Pradesh – 2005 and 2010 
Introduction 
As was discussed in chapter 1, dyslipidaemia is an important determinant of cardiovascular disease in India18. 
On the background of limited data on temporal trends in cholesterol levels in rural India, this is a timely study 
focusing on the potential changes in these cardiovascular risk factors. This is pertinent in a geographic area 
which is likely to be at high risk for an epidemic of cardiovascular disease and the identification of increasing 
trends in risk factor prevalences will guide effective interventions and assess the severity of the problem. 
This analysis was based on the lipids data extracted from the GC13 survey. A comparison with the APRHI 
study13 is included. The analytes measured were total cholesterol (TC) and low density lipoprotein (LDL) along 
with physical measurements of height, weight and body mass index (BMI). 
Methods 
The survey structure was as described in chapter 2. The participants aged 30 and above were included in this 
analysis. The finger pick dried blood spot (DBS) was collected on filter paper for the 2010 GC13 study. The 
samples were dried at room temperature, packaged in plastic and refrigerated at 2 – 4oC before 
transportation. Final biochemical assays for analysis were done at the Nizam’s Institute for Medical Sciences, 
Hyderabad. The analytes were eluted from the filter paper using a phosphate buffer solution. The assays were 
based on a Randox colorimetric end point assay (Randox Laboratories Ltd, UK). Participant’s characteristics 
such as weight, height and body mass index (BMI) were recorded. The 2005 APRHI study made use of fasting 
blood lipid samples collected via traditional venepuncture. Statistical analysis was done as previously described 
in chapters 2 and 4. Continuous variables were compared using the unpaired Student’s t test. 
Results 
The mean TC decreased from 4.6 mM (4.5 mM – 4.7 mM, 95% CI) to 3.4 mM (3.3 mM – 3.5 mM, 95% CI), 
p<0.001. The mean LDL decreased from 2.9 mM (2.8 mM – 3.0 mM, 95% CI) to 1.5 mM (1.4 mM – 1.6 mM, 
95% CI), p<0.001. The significant fall in both blood lipids was consistent across all age and sex groups (Table 5-
1). The weight and BMI had statistically significant increases from APRHI to GC13 but the average height was 
unchanged. When only the four common villages were included, the TC decreased from 4.8 mM (4.7 mM – 4.9 
mM, 95% CI) to 3.3 mM (3.1 mM – 3.5 mM, 95% CI) and the LDL decreased from 3.0 mM (2.9 mM – 3.1 Mm, 
95% CI) to 1.4 mM (1.3 mM – 1.5 mM, 95% CI). All the data appeared to be normally distributed except the 
GC13 TC and LDL results which showed right skewing (Figures 5-1 and 5-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 40 of 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.2
.4
.6
D
e
n
s
it
y
0 2 4 6
ldl_mmol
0
.2
.4
.6
.8
D
e
n
s
it
y
0 2 4 6
ldl_mmol
FIGURE 5-1. LDL CONCENTRATIONS FROM EACH STUDY. APRHI ON THE LEFT, GC13 ON THE RIGHT. ‘DENSITY’ ON 
THE VERTICAL AXIS REFERS TO THE RELATIVE PROPORTIONS OF EACH LDL LEVEL ON THE HORIZONTAL AXIS. 
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FIGURE 5-2. TC CONCENTRATIONS FROM EACH STUDY. APRHI ON THE LEFT, GC13 ON THE RIGHT. ‘DENSITY’ ON 
THE VERTICAL AXIS REFERS TO THE RELATIVE PROPORTIONS OF EACH TOTAL CHOLESTEROL LEVEL ON THE 
HORIZONTAL AXIS. 
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TABLE 5-1. MEAN LEVELS OF TOTAL CHOLESTEROL, LDL, WEIGHT AND BODY MASS INDEX OVERALL AND BY AGE AND SEX FOR APRHI (2005) AND GC13 (2010). 
 
 
    Total cholesterol (mmol/L)   LDL cholesterol (mmol/L)   Weight (kg)   BMI (kg/m2) 
                         
  
APRHI  
 
GC13  
 
APRHI  
 
GC13  
 
APRHI  
 
GC13  
 
APRHI  
 
GC13  
  
 S.E. 
  
S.E. 
  
S.E. 
  
S.E. 
  
S.E. 
  
S.E. 
  
S.E. 
  
S.E. 
                       
Overall 
 
4.6 0.04 
 
3.4 0.05 
 
2.9 0.03 
 
1.5 0.03 
 
54.4 0.2 
 
56.0 0.24 
 
21.9 0.07 
 
22.7 0.09 
30-39 
 
4.3 0.08 
 
3.3 0.09 
 
2.7 0.06 
 
1.5 0.06 
 
54.3 0.36 
 
56.4 0.45 
 
21.6 0.13 
 
22.3 0.15 
40-49 
 
4.8 0.09 
 
3.4 0.11 
 
3 0.07 
 
1.6 0.07 
 
56.4 0.41 
 
57.6 0.48 
 
22.6 0.14 
 
23.2 0.18 
50-59 
 
5 0.07 
 
3.7 0.12 
 
3.2 0.06 
 
1.6 0.08 
 
55.3 0.45 
 
56.5 0.53 
 
22.5 0.16 
 
23.2 0.18 
60+ 
 
4.7 0.08 
 
3.2 0.06 
 
2.9 0.06 
 
1.5 0.04 
 
51.5 0.37 
 
53.9 0.48 
 
21.4 0.14 
 
22.2 0.17 
                         Men, all 
 
4.5 0.06 
 
3.5 0.08 
 
2.8 0.05 
 
1.6 0.05 
 
57.9 0.29 
 
59.0 0.35 
 
21.6 0.09 
 
21.9 0.11 
30-39 
 
4.3 0.12 
 
3.5 0.15 
 
2.7 0.1 
 
1.5 0.11 
 
57.7 0.54 
 
60 0.6 
 
21.1 0.18 
 
21.8 0.19 
40-49 
 
4.6 0.15 
 
3.6 0.16 
 
2.9 0.1 
 
1.7 0.11 
 
59.5 0.59 
 
59.5 0.7 
 
22.2 0.19 
 
22.1 0.23 
50-59 
 
4.8 0.11 
 
3.7 0.19 
 
3.1 0.09 
 
1.8 0.11 
 
59.1 0.62 
 
59.6 0.81 
 
22.1 0.2 
 
22.4 0.25 
60+ 
 
4.4 0.1 
 
3.1 0.1 
 
2.7 0.08 
 
1.3 0.05 
 
55.5 0.5 
 
57.2 0.69 
 
21 0.16 
 
21.7 0.23 
                         Women, all 
 
4.8 0.06 
 
3.2 0.06 
 
3 0.04 
 
1.5 0.03 
 
50.7 0.27 
 
53.5 0.32 
 
22.3 0.11 
 
23.3 0.13 
30-39 
 
4.4 0.11 
 
3.2 0.11 
 
2.8 0.08 
 
1.5 0.06 
 
51 0.48 
 
53.2 0.61 
 
22 0.2 
 
22.7 0.23 
40-49 
 
5 0.1 
 
3.1 0.12 
 
3.2 0.09 
 
1.4 0.08 
 
52.8 0.55 
 
55.9 0.66 
 
23.1 0.21 
 
24.3 0.27 
50-59 
 
5.2 0.09 
 
3.4 0.15 
 
3.3 0.07 
 
1.6 0.1 
 
51.4 0.61 
 
54 0.66 
 
22.8 0.25 
 
23.8 0.26 
60+  5 0.12  3.3 0.08  3.1 0.08  1.6 0.06  47.8 0.54  50.7 0.62  21.8 0.22  22.7 0.25 
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Discussion 
These data suggest a large drop in mean blood lipids levels in the five years between 2005 and 2010 accompanied by a 
significant weight and BMI increase. This combination of changes and the magnitude of the blood lipid changes are 
implausible and almost certainly reflect systematic under-estimation of blood lipid values in the 2010 data. 
For context, the normal range LDL in the US population is 2.3 mM to 3.4 mM with an average of 3.1 mM116. It is biologically 
and epidemiologically challenging to explain the fall in mean LDL observed here (2.9 Mm to 1.5 mM) which would take the 
mean value in Andhra Pradesh from within the US normal range to a value less than half of the US mean in the space of 
only five years. By way of further context, a study in rural college students of Andhra Pradesh aged 18-22 done in 2011 
showed a mean LDL of 1.86 mM and TC of 3.34 mM117.  While markedly lower than the levels observed in the US, these 
values are still significantly greater than those recorded for the general adult Andhra Pradesh population in the 2010 
survey.  Students of this age would be anticipated to have lower, not higher, mean lipid levels compared to the general 
population.  Similarly in a recent study representative of most of India, the rural subgroup recorded a mean LDL of 2.30 
mM and TC of 3.98 mM40 further highlighting the peculiarity of the GC13 values. 
The GC13 lipid measurements were based on assays done on DBS and as shown in chapter 4 these appear to be unreliable 
of lipid assays and there is a strong likelihood that the biochemical analysis was biased and incorrect because of the use of 
DBS.  The right skewing of only the blood analyte data in GC13 for TC and LDL also raises concerns about the integrity of 
the biochemical analysis technique or storage conditions of the GC13 samples. All of the other data showed the 
anticipated approximate normal distribution. A possible explanation would be that the higher LDL and TC values were not 
correctly measured resulting in both the lower than expected LDL and TC means and also the right skewing of the 
distributions. This could occur from degradation of the molecules while in storage, lack of complete elution from the filter 
paper before analysis or a problem with the colorimetry assay. 
A similar survey structure and statistical analysis was used for both the blood analytes and the physical measurements but 
only the distributions of the analyte data are skewed. It is unlikely, therefore, that it is a statistical analysis error leading to 
the unusual LDL and TC results as the physical measurement data are normally distributed, as expected. The only 
additional step in the analysis of the blood analytes was the use of post-stratification weights after the final step of 
selection of DBS participants. This weighting procedure was re-examined and found to be robust. Also if the weights were 
the issue then there would be a systematic error in all the LDL and TC measurements which would not lead to the skewed 
distribution but rather a normal distribution with a shifted mean.  
A further weakness in the temporal comparisons of this study was the slightly different sampling strategy used for the 
2005 and 2010 populations.  The subgroup analysis of the common villages does, however, provide results consistent with 
those observed in the total dataset. The survey methods and statistical analyses are based upon established approaches45 
and are unlikely to have introduced substantive inaccuracies. The use of the Student’s t test is justified despite some non-
normal distributions of the data, since the sample sizes are large and the variances are similar118. 
In conclusion, the changes in lipids observed here are almost certainly a consequence of artefact and are very unlikely to 
reflect true changes in population lipid levels in this region.  The observed increase in BMI and the rising rates of diabetes 
are both signs of adversely evolving cardiovascular risk factors and it is likely that LDL and TC levels in this population are 
either static or deteriorating.  For further such studies it is recommended that traditional venous blood sampling be used 
at least until DBS for LDL and TC sampling has been further characterised. 
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Chapter 6. Discussion and Conclusions 
These data provide new insight into the evolving state of cardiovascular risk factors in rural Andhra Pradesh and highlight 
the need for standardised approaches to monitoring of changes over time. The data show that the prevalence of diabetes 
mellitus and dysglycaemia is high and most likely increasing but fail to establish a clear pattern for blood lipids.  That said, 
with body weight and body mass index (BMI) both increasing, it is more likely that blood lipid levels are deteriorating than 
improving. 
The observed 72% increase in diabetes mellitus prevalence in the Godavari region of rural Andhra Pradesh between 2005 
and 2014 is large. For comparison, a recent set of predictive figures on diabetes suggested that by 2030 there will likely be 
a 69% increase in the numbers of adults with diabetes in developing countries and a 20% increase in that of developed 
countries97. The increase in diabetes in Andhra Pradesh defined by our data is far greater in magnitude since it has 
occurred in just a decade.  If true and if widespread throughout India, the predictions made that infer a rise in India’s 2010 
population of 50.8 million with diabetes to 87 million by 203097 would be a gross under-estimate.  Of note, these 
predictions are significantly higher than previous predictions made just 5 years earlier119. In this previous estimate, it was 
thought that by 2030 the global diabetes prevalence would reach 4.4%, it has been shown that in 2010 that global 
prevalence has already crossed 6.4%. In 2015 there is an 8.6% prevalence with over 65 million Indians with diabetes120. 
This underlines the challenge of estimating diabetes prevalence at either a national or an international level. 
The primary analysis in Chapter 4, based on only fasting blood glucose levels, revealed an increasing prevalence of 
dysglycaemia in rural Andhra Pradesh. This was in parallel with BMI and was driven by the women in the population. There 
was a greater increase in BMI for women than men but this alone would not account for the majority of dysglycaemia and 
diabetes prevalence changes being in women. There have been suggestions that the women of rural India often place their 
own health needs after those of the men and the rest of the family and these data could in part be a manifestation of such. 
It has been noted that in South Asia women often have limited access to healthcare facilities and education due to 
negative social structures and customs121. A recent review identifies that women across India have higher prevalences of 
obesity. The suggested predisposing factors for obesity in Indian women included sedentary behaviour, imbalanced diets, 
sequential post-partum weight gain and cultural reasons for decreasing physical activity post-partum122. These factors are 
potential explanations for the comparatively higher increase in BMI and dysglycaemia seen in women compared to men. 
On viewing the secondary analysis in Chapter 4, the prevalence of diabetes in the population in the Godavari region of 
Andhra Pradesh appears to have undergone a significant increase when considering the APRHI and GC13 results in 
isolation. Adding in the SMARTHealth data it seems that the dysglycaemia prevalence is decreasing (Figure 4-1b). This 
presents a confusing picture not apparent in the primary analysis and raises the issue of diagnostic standards since GC13 
used glycosylated haemoglobin (HbA1c) but APRHI and SMARTHealth used plasma glucose levels. Both have been 
standardized with the diagnostic values determined by the rate of incidence in microvascular diseases, for example, 
diabetic retinopathy incidence43. An HbA1c over 6.5%, fasting plasma glucose over 7 mM and random plasma glucose over 
11.1 mM all lead to a significantly increased risk of developing microvascular diabetic disease43, therefore it is expected 
that these standards would return similar population diabetes prevalences. Unfortunately this is not the case as there have 
been variations due to ethnicity or presence of haemoglobin subtypes in some populations123. Since the adoption of 
diagnosis by HbA1c concerns have been raised about the sensitivity and a correction to the diagnostic cut off has been 
suggested124. Even so, it has also been reported that groups diagnosed by either method are both still at increased risk of 
microvascular diabetic disease43, 125. Therefore, the different diabetes prevalence identified by HbA1c in these studies may 
indicate a separate but overlapping population at risk of diabetic complications when compared to the group diagnosed 
using fasting plasma glucose. For this reason the extremely high diabetes prevalence seen in GC13 may not be completely 
a matter of overestimation, it may indicate a larger population at risk of cardiovascular disease126. This is consistent with 
previous studies showing the progressive rise in cardiovascular risk factors in India. In Chapter 1, the trend for diabetes 
prevalence in rural Tamil Nadu was noted to be potentially exponentially increasing in that rural region (Figure 1-1), even 
though the absolute prevalence did not reach the same value found here. The most recent study in that region was in 2006 
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with a prevalence of 9.2% (8.0% – 10.5%, 95% CI). By the current stage that number could be approaching the prevalence 
levels shown here in rural Andhra Pradesh, assuming that there were no interventions.  
The trend in the Godavari region cannot be interpreted with only the two data points on diabetes prevalence particularly 
with such uncertainty over the meaning of the prevalence diagnosed by two different methods. In this case the 
SMARTHealth study permits a greater insight into the problem. The results confirm that GC13 had either identified a 
different at risk population or overestimated diabetes prevalence due to a bias caused by the use of HbA1c-based criteria. 
Another approach to analysis was to combine the diabetes and prediabetes prevalence as a composite metric – 
dysglycaemia, and view that aggregate as an indication of increased cardiovascular risk. The changes in the level of 
dysglycaemia over time, rather than diabetes or prediabetes individually, showed a more plausible variation (Figure 4-1). 
This indicates that the group that GC13 identified as having diabetes included some of the population that was diagnosed 
as prediabetic according to plasma glucose levels in APRHI and SMARTHealth. Therefore, the diabetes prevalence was 
significantly higher but prediabetes prevalence was much lower in GC13 compared to APRHI and SMARTHealth (Figure 4-
1b). Essentially, it appears that the diagnostic cut off for diabetes should be higher when using HbA1c for this population. 
Nevertheless, the changes in dysglycaemia are relevant to changes in cardiovascular risk profiles. The increase shown in 
the primary analysis suggests that diabetes rates are still on the rise. The contrasting decrease in dysglycaemia found in 
the secondary analysis was likely a consequence of relying mostly on non-fasting blood glucose levels in SMARTHealth, as 
was discussed in Chapter 4.    
The blood lipids data has raised some interesting questions about the quality of analysis and biochemical methods.  The 
decrease seen in blood lipids is unfeasibly rapid. On further inspection, and when viewed alongside the diabetes data, the 
decrease in blood lipids from 2005 to 2010 looks to be inconsistent with the increase in diabetes and BMI from 2005 to 
2014 (figure 4-1a). A likely scenario is that there was a biochemical analytic error of sorts as expounded by the discussion 
in chapter 5. It would be preferable to repeat the study on blood lipids in the region using either traditional venepuncture 
based measurements or using dried blood spots (DBS) once it has been adequately characterised for these analytes. As 
seen in Chapter 3, the data is currently sparse and uniform methods for storage, elution and subsequent correction of the 
data need to be determined before further use of DBS for lipids.  
The difficulty in assessing blood lipid levels in this study highlights the issues in describing blood analyte levels in 
developing regions. Chapter 3 examines the suitability of DBS as a possibility. It has been shown that DBS is a feasible 
option for detecting diabetes prevalence rates. It has the potential to become the standard method in studies involving 
large-scale population sampling. This is true particularly in resource poor regions where it has the greatest comparative 
advantage over traditional venepuncture sampling. It requires minimal training and is generally easy to store and safe to 
handle. DBS is shown to be reliable in diagnosing diabetes in a population sample where the individual inaccuracies will be 
averaged out over the mean. Specifically, the proportion of the sample who have an HbA1c above 6.5% can be adequately 
assessed using DBS and therefore population diabetes prevalence can be inferred, depending of course on the reliability of 
the survey structure and analysis.  
For studies of cardiometabolic risk factors it would be advantageous to sample multiple blood analytes with a single DBS. 
For example, if a population can be sampled for HbA1c, total cholesterol, low density lipoprotein (LDL), high density 
lipoprotein (HDL) and triglycerides simultaneously using only a single drop of blood per person, then sampling would be 
seen as a more feasible task for potential investigators. This may encourage both more studies to be contemplated and 
more participants in each study. To achieve this utility from DBS, further studies of LDL, HDL, total cholesterol and 
triglycerides are required to characterize the relationship of DBS to venepuncture samples. In the background of changing 
disease burdens and risk factors this is of particular importance as it will allow more frequent sampling and follow up of 
specific regions. This will impact health policy decisions at a later stage where more informed decisions can be made to 
target the cardiovascular risk factors that pose the greatest threat to particular regions. The GC13 survey is a preliminary 
model of how this can be achieved relatively efficiently with DBS, only the technique requires some optimisation. 
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The value in characterizing the relationship between DBS and venous HbA1c is apparent in chapter 4. When presented with 
such a significant increase in diabetes prevalence from APRHI to GC13, one of the questions raised was about the use of 
different methods in the two surveys. The results of the meta-analysis were necessary to show that the unrealistic rise in 
diabetes over five years was not likely to be due to any issues with using DBS in GC13. This is particularly evident since the 
GC13 results were standardized using the regression equation derived in chapter 3 so as to be more comparable with the 
data in APRHI. This allowed attention to be diverted towards investigating other potential explanations for the results in 
GC13 which can be found in Appendix 1. Finally, the likely explanation for the excessive diabetes prevalence in GC13 was 
attributed to a non-robust diagnostic cut-off for diabetes in this population. Unfortunately there was no data available to 
assess how LDL measurements by DBS should be approached but total cholesterol levels seen in GC13 were adjusted for 
the use of DBS with a regression equation from the systematic review.  
In placing this work in context we find that there has been a recent swing in the focus of cardiovascular epidemiology 
worldwide and increasing amounts of the latest literature has focused towards the rising epidemic of cardiovascular 
diseases in the developing world. These latest studies (Chapters 4 and 5) in rural Andhra Pradesh will provide further 
knowledge on how cardiovascular risk factors evolve in these environments and will highlight any differences from the 
progression of the same diseases in urban India and the developed world more broadly. In 2011, ‘Chronic diseases and 
injuries in India’ revisited the issues presented in ‘Responding to the threat of chronic diseases in India’, another review 
published 6 years earlier. At the moment there are a wide array of possible primary and secondary prevention strategies 
for cardiovascular diseases but the access to prevention is limited, especially in the more rural and poorer regions127. In 
addition, a large proportion of current care for chronic diseases in India is in the private medical sector and this becomes 
prohibitively expensive for much of the population who are at risk. The authors advocate for a strengthening of social and 
public policy charters to allow the efficient implementation of appropriate interventions.  
The World Health Survey of 2003 is highlighted on in the ‘Chronic diseases and injuries in India’ publication. This 2003 
survey had a stratified multistage cluster design and was done in the Indian states of Assam, Karnataka, Maharashtra, 
Rajasthan, Uttar Pradesh and West Bengal. The purpose of the study was to assess chronic disease symptoms, previous 
diagnosis rates and economic status of the participants. A distinct pattern of an initial uptake of harmful health behaviours 
in the early stages of socioeconomic advancement was identified. Even though socioeconomic development generally 
tends to be associated with healthier behavioural changes, a steep climb in economic growth 128 has led to a reduction of 
physical activity and increasing rates of obesity and diabetes. Current levels of health literacy and public awareness are 
inadequate and the result is the more affluent class are slowly adopting healthier lifestyles while the poorer groups are 
somewhat neglected. The fact that over 20% of the Indian population are smokers20 is further evidence of the need to 
improve public awareness of the well understood health hazards which are assumed as standard knowledge.  
The authors of ‘Responding to the threat of chronic diseases in India’ also provide specific estimates for the impact of 
chronic diseases based on the trends and data observed to 201112. It is estimated that chronic diseases will move to 
become accountable for almost 75% of all mortality in India by the year 2030. The number of years of life lost due to 
coronary heart disease in those younger than 60 is projected to increase from the 7.1 million observed in 2004 to 17.9 
million in 2030 - this is greater than that expected in China, Russia and the USA combined. Recommendations for 
prevention include population and individual focused efforts such as tobacco control, reduced dietary salt intake, blood 
pressure lowering medications, cholesterol lowering medications and combination drug treatment. With the common 
combination drug treatments such as an antihypertensive and a statin, scaling up production to provide for 50% of the 
total high risk individuals in India would avert 5.8 million deaths over 10 years. The cost would be less than 1 USD per 
person per year for all the high risk group if the treatment is targeted to those who would receive the most benefit, by 
effective screening of risk factors. This includes the cost of medications, health service delivery, laboratory testing and 
program administrative costs relevant to India, all summated and divided per head.129 In the public policy space, an 
economic modelling study130 has predicted that taxation on sugar sweetened beverages would mitigate rising obesity and 
type 2 diabetes with particularly large effects in young rural men rather than the expected urban beneficiaries. This 
provides another perspective on what interventions might be most effective. 
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Further pertinent predictions of cardiovascular disease risk are presented in ‘Distribution of 10-year and lifetime predicted 
risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results)’. This 
article is based on a nationwide risk factor surveillance study with 10 054 disease free adult Indians who had their 
cardiovascular disease risk stratified into groups. The main findings are that high short term coronary heart disease risk 
was prevalent in more than one fifth of the population at 23.5% (22.7% - 24.4%, 95% CI). Also almost half, 48.2% (47.1% - 
49.3%, 95% CI), of the participants who were classified as low short term risk were found to have a high predicted total 
lifetime risk. The fraction of the participants who had optimal levels of cardiovascular risk factors was 15.3% (14.6% - 
16.0%, 95% CI). This was further divided into 20.6% (18.7% - 22.6%, 95% CI) of individuals from the highest educational 
group having optimal risk factors and only 8.8% (7.7% - 10.5%, 95% CI) of the lowest educational group having the same. 
This provides evidence of the socioeconomic status based health disparities within India. There is also a review of the 
progress made on previous recommendations made in 2005 for cardiovascular disease and diabetes. It is worth 
reproducing and reviewing the relevant list of recommendations and their current progress as presented by the authors of 
this review:   
- Tobacco control: Banned on films and TV programmes. Ban on specific public places. 
- Production and supply of healthy foods: Nil 
- Regulation of unhealthy foods: Nil 
- Urban planning to promote physical activity: Nil 
- Community empowerment through health promotion programmes: National Rural Health Mission aims to 
integrate health promotion activities of the National Programme for prevention and control of diabetes, CVD and 
Stroke into its overall goals 
- Health system strengthening aimed at early detection of high risk individuals: Guidelines developed. Medical 
officer’s manual on prevention and control of diabetes, CVD and stroke. Health workers guide with a flip chart for 
community awareness. India-specific physical activity guidelines 
- Effective secondary prevention of chronic disease: Involvement of medical colleges and private practitioners in 
setting up pilot special clinics. 
- Cost effective and lifesaving acute care: Nil 
 
From this there is some cause for optimism but there are many areas of public health policy that are yet to be harnessed 
to optimally tackle the challenge of the cardiovascular disease epidemic in India, of which a substantial component is the 
rising diabetes levels seen in the rural regions. 
It must also be considered that there are other, less modifiable factors that may augment or assist the rapid rises of 
cardiovascular diseases and diabetes in India. Many have proposed that South Asians have a higher propensity for diabetes 
and cardiovascular disease for reasons other than demographics and urbanization alone43, 131-135. One study, ‘Serum 
cholesterol and coronary artery disease in populations with low cholesterol levels: The Indian paradox’, finds that in Indian 
populations serum total cholesterol level is directly related to coronary heart disease prevalence even amongst those with 
a low cholesterol (<5.18 mM)131. This result indicates that we may need to consider lipid levels as a continuous spectrum of 
risk rather than only at specific cut-off points. It is possible then that there may be an advantage to lowering total 
cholesterol levels to below the normal range considered optimum. 
There are also questions in the literature of increased central obesity conferring a greater risk for Indian populations than 
for other groups. There is a hypothesis proposed in ‘Why might South Asians be so susceptible to central obesity and its 
atherogenic consequences? The adipose tissue overflow hypothesis’ as to the metabolic disturbances that may be affecting 
this population. The authors propose that the fat compartment of superficial subcutaneous adipose tissue has a lower 
total capacity in South Asians compared to Caucasians. Therefore excess fat is further deposited in the more atherogenic 
and metabolically active deep subcutaneous tissue and visceral adipose tissue compartments. This is presumed to lead to 
accelerated vascular disease as has been observed with disease occurring in younger age groups amongst the Indian 
population. 
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Genetic studies have also suggested some differences in the susceptibility of Indians to diabetes mellitus. The authors of 
‘Genetic predisposition to type 2 diabetes among Asian Indians’ determine that there are certain genes predisposing 
Indians to developing diabetes while there are also other genes which are normally protective against insulin resistance in 
Caucasians but do not appear to be protective for the Indian population115. More specifically, a recent publication has 
identified a new type 2 diabetes mellitus associated gene locus at 2q21136. This was a two stage genome wide association 
study of diabetes in 12 535 Indians. The pertinent results showed that both the previously known loci and the newly 
distinguished 2q21 together explained 7.65% of the variance in the risk of diabetes in Indians. This new evidence for a true 
genetic predisposition of the Indian population towards diabetes can partially explain the high diabetes rates seen in many 
parts of India. This is notwithstanding that India is not the only area with rapid urbanization and demographic changes but 
still appears to be one of the most severely affected by the diabetes and cardiovascular disease epidemic. 
The overall conclusions of my work are that the DBS technique is very promising in its application to resource poor regions 
when surveying cardiovascular risk factor blood analytes but needs some further work to determine the best methodology 
for each analyte. The rural Andhra Pradesh population followed up in these surveys have shown an increasing 
dysglycaemia prevalence but changes in blood lipid levels were difficult to determine with any certainty. The proportion of 
the population with an HbA1c over 6.5% is very concerning for the future development of diabetic complications and 
cardiovascular disease. More data is required on blood lipid levels in this population to ensure adequate surveillance of 
evolving cardiovascular risk factors in a region likely undergoing significant changes in cardiovascular disease. The 
increasing dysglycaemia prevalence requires urgent attention, particularly in the context of global and regional shifts in the 
burden of disease from non-communicable diseases. 
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Appendix 1. Assessing Potential Sources of Bias in GC13  
Introduction 
In light of the diabetes prevalence results in GC13, further queries can be made regarding the nature of any errors or 
possible overestimation of diabetes in the GC13 data. As was shown in chapter 3, error is unlikely to be due to the use of 
DBS. In chapter 4 it was proposed that GC13 had likely overestimated diabetes and underestimated prediabetes. The 
evidence was seen in the variation amongst the diabetes and prediabetes aggregates which showed a more 
understandable trend than what appeared to be a severe spike in diabetes prevalence as seen in GC13. To provide further 
insights into the comparison of APRHI and GC13 and possible explanations for the results, a propensity score matched 
analysis137 was undertaken. It was hypothesized that once the participants in APRHI and GC13 were matched on 
propensity scores, any differences in target population or sampling errors would be minimized therefore allowing diabetes 
prevalence to be assessed with little residual confounding effects. The purpose of this was to search for any bias in the 
GC13 data that could have been from confounding factors, eg. Sample BMI distribution or exercise habits. The results from 
each interviewer involved in the study were also examined, searching for any clear bias amongst individual interviewers 
due to poor technique. 
Methods 
Potential effects on diabetes prevalence due to differences in background covariates in the APRHI and GC13 samples were 
explored using a propensity score matching method. This involved assigning scores to each participant depending on their 
propensity to be in either study based on their background covariates; age, sex, body mass index (BMI), smoking status, 
previous school education, controlling weight, physical exercise, reducing dietary salt and fat or past history of angina, 
stroke or myocardial infarction. These scores were derived using a logistic regression of study, either APRHI or GC13, on 
the background covariates. Then the diabetes prevalence was compared only within those with similarly matched 
propensity scores thereby reducing potential confounding error. The matching procedure was single nearest neighbour 
matching without replacement and with set calipers. This involved matching a participant in APRHI to only the nearest 
participant in GC13. This must also be within a minimum propensity score difference, the caliper. Therefore the matched 
pairs never had a difference in propensity score greater than the chosen caliper value. The caliper value used was 0.2 of 
the standard deviation of the logit propensity score as this was shown as optimal138. 
The GC13 results were separated into mean HbA1c by interviewer and questionnaire diabetes prevalence by interviewer. 
This was to detect potential sample collection error and incorrect recording of previously known diabetes respectively. 
Analysis of variance (ANOVA) was conducted on the mean HbA1c by interviewer data. All statistical analysis was using the 
statistical software package STATA 11.0 (StataCorp, College Station, TX, USA) with the PSMATCH2 module applied to 
conduct the propensity score matched analysis. 
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Results 
The propensity score matching uncovered a persistent bias in the GC13 data compared to APRHI even after accounting for 
the other measured covariates (Figure A1-1). As expected, the propensity score matched samples had little difference in 
the background covariates measured but it did not reduce the difference in diabetes prevalence between APRHI and GC13. 
This difference increased after matching process. 
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FIGURE A1-1. PROPENSITY SCORE MATCHED ANALYSIS. BIAS IN DIABETES PREVALENCE AND 
OTHER COVARIATES BETWEEN APRHI AND GC13. TOP PANEL SHOWS THE BIAS BETWEEN 
APRHI AND GC13 FOR EACH COVARIATE. THE PROPENSITY SCORE MATCHING PROCESS HAS 
REDUCED THE BIAS AND THE MATCHED SUBGROUP NOW HAVE SIMILAR LEVELS OF 
BACKGROUND COVARIATES. THE BOTTOM PANEL DEMONSTRATES THE EFFECT ON THE BIAS IN 
DIABETES PREVALENCE, BETWEEN APRHI AND GC13, BEFORE AND AFTER MATCHING FOR THE 
OTHER COVARIATES. THE BIAS OR DIFFERENCE IN DIABETES PREVALENCE IS NOT SIGNIFICANTLY 
AFFECTED WHEN WE USE THE PROPENSITY SCORE MATCHED SUBGROUP. 
 Page 57 of 93 
 
No particular interviewer could clearly be found responsible for spurious results due to either incorrect blood spot 
collection or data entry (Figure A1-2). An ANOVA of the data, divided into groups by interviewer ID, confirmed the 
differences between interviewers were non-significant, p = 0.881. 
A subgroup analysis of the 4 common villages showed a non-significant increase in diabetes prevalence but prediabetes 
decreases consistent with the general data (Table A1-1). 
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FIGURE A1-2. RESULTS BY INTERVIEWER. ASSESSING FOR POTENTIAL DATA COLLECTION ERRORS IN GC13. 
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TABLE A1-1. PREVALENCE OF DIABETES AND PREDIABETES IN 2005 AND 2010 BY AGE AND SEX FOR THE FOUR VILLAGES COMMON TO 
BOTH APRHI AND GC13. 
 2005 
% (95%CI) 
2010 
% (95%CI) 
Absolute Difference % (95%CI) 
p-value 
DIABETES    
All 17.6 (14.5-20.7) 21.9 (14.9-29.0) 4.30 (-3.34 to 11.9) p=0.270 
Men 18.9 (14.4-23.3) 19.3 (10.6-28.0) 0.40 (-9.32 to 10.1) p=0.936 
Women 16.3 (12.1-20.6) 25.2 (13.9-36.5) 8.90 (-3.12 to 20.9) p=0.147 
PREDIABETES    
All 35.0 (31.1-38.8) 15.6 (9.61-21.6) -19.4 (-26.5 to -12.3) p<0.001 
Men 34.8 (29.5-40.2) 16.3 (8.16-24.4) -18.5 (-28.2 to -8.83) p<0.001 
Women 35.1 (29.7-40.6) 14.8 (5.84-23.8) -20.3 (-30.8 to -9.83) p<0.001 
 
Discussion 
In effect, the propensity score matching allows an observational study to simulate some characteristics of randomized 
studies. It minimizes the effect of confounding factors amongst treatment and intervention groups, in this case the APRHI 
and GC13 studies. These results of the propensity score analysis argue against any of the measured covariates being a 
major contributor to the increased diabetes seen in GC13, although this does not rule out any unmeasured confounders. 
Considering the difference between the diabetes prevalence values were not reduced by matching on the sample 
background characteristics it is seems likely that there is another cause for such a sharp increase in diabetes prevalence 
from 2005 to 2010. The suggestion in Chapter 4 that the diagnostic cut-off definitions based upon fasting plasma glucose 
and HbA1c are not equivalent for this population seems to be the remaining explanation.  
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1. Unemployed/ retired  
2. Housewife  
3. Skilled manual worker  
4. Unskilled manual worker  
5. Owner of business or farm  
6. Office worker/ non professional  
7. Professional  
8. Student  
 
Appendix 2. APRHI Survey Questionnaire  
 
Relevant questions for this work are included below: 
 
THANK YOU FOR AGREEING TO TAKE PART IN THIS SURVEY TO FIND OUT ABOUT 
THE RISKS OF HEART ATTACK, STROKE AND OTHER CHRONIC DISEASES FOR 
RESIDENTS OF RURAL ANDHRA PRADESH. MOST OF THE QUESTIONS I WILL ASK 
WILL BE ABOUT YOU, AND A FEW WILL BE ABOUT YOUR HOUSEHOLD. AT THE 
END, THERE WILL BE A BRIEF PHYSICAL EXAMINATION. 
 
 
1.   How old are you?    |__|     | 
 
2.   Can you read and write? 
 
1.   Yes 
2.   No 
 
3.  What is the highest level of education that you have completed? MARK ONE 
BOX ONLY. 
1.   No formal schooling 
2.   Primary school 
3.   Secondary school 
4.   Higher education (eg. Diploma/Technical/University studies) 
 
 
4.   Which of these best describes your usual main occupation? READ OUT AND 
MARK ONE BOX ONLY. 
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5.   How many people live in your HOUSEHOLD?      |__|     | 
 
 
 
6.  What is the combined MONTHLY income of everyone in your HOUSEHOLD, 
including yourself?     |__|            |            |            |             |            |     | Rs 
 
 
 
7.   In an average MONTH, how much do you think your HOUSEHOLD spends on 
i.  Medication (including prescription tablets and other medicines) 
|__|            |            |            |             |            |     | Rs 
ii.  Other health care (including doctor consultations, tests, procedures and 
travel)    |__|            |            |            |             |            |     | Rs
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1. Excellent 
2. Very Good 
3. Good 
4. Fair 
5. Poor 
 
1. Excellent 
2. Very Good 
3. Good 
4. Fair 
5. Poor 
 
 
 
 
 
 
 
8. Which of these best describes your quality of life? MARK ONE BOX 
 
 
 
 
 
 
 
9.   Which of these best describes your health? MARK ONE BOX
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1 Heart attack Yes No 
2 Angina Yes No 
3 Stroke Yes No 
4 Peripheral vascular disease (disease of the arteries) Yes No 
5 Diabetes (sugar) Yes No 
6 Hypertension (high blood pressure) Yes No 
7 High cholesterol Yes No 
 
1 Heart failure Yes No 
2 Rheumatic heart disease or  valve disease Yes No 
3 Anaemia Yes No 
4 Tooth or gum disease Yes No 
5 Cataract Yes No 
6 Thyroid disease Yes No 
7 Depression Yes No 
8 Chronic lung disease (NOT asthma) Yes No 
9 Asthma Yes No 
10 Pneumonia Yes No 
11 Tuberculosis Yes No 
12 Malaria Yes No 
13 HIV/AIDs Yes No 
14 Cancer Yes No 
15 Epilepsy Yes No 
16 Stomach ulcer Yes No 
17 Malnutrition Yes No 
 
 
 
 
 
I WILL NOW ASK YOU A FEW QUESTIONS ABOUT WHAT YOUR DOCTOR 
HAS TOLD YOU ABOUT YOUR HEALTH 
10. Have you ever been told by a doctor that you have had any of the following? 
 
 
 
 
 
 
 
 
 
 
 
11. Have you ever been told by a doctor that you have any of the following chronic 
medical problems?
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I AM NOW GOING TO ASK YOU ABOUT FACTORS RELATED TO YOUR 
FAMILY AND LIFESTYLE 
 
 
12. Have any of your close relatives (mother, father, brothers, sisters) had a heart 
attack before the age of 60 years? 
 
1. Yes 
2. No 
 
13. Have any of your close relatives (mother, father, brothers, sisters) had a stroke 
before the age of 60 years? 
 
1. Yes 
2. No 
 
14. Have any of your close relatives (mother, father, brothers, sister) been 
diagnosed with diabetes? 
 
1. Yes 
2. No 
 
15. On average, how much physical activity do you do each day during working 
hours? MARK ONE BOX 
 
1. LOTS Eg. Lifting heavy weights, construction work, labourers, 
running 
2. MEDIUM Eg. Bike riding, rickshaw drivers, carrying buckets of water or 
loads of laundry to and from wells multiple times a day, 
walking long distances up and down hills 
3. LIGHT 
ACTIVITY 
Eg. Walking on the level, standing all day working at a shop, 
housework such as cooking, cleaning in the house 
4. ALMOST 
NONE 
Eg. Seated at a desk, driving a car, watching television, 
reading, resting 
 
16. On average, how much physical activity do you do each day after working hours? 
MARK ONE BOX 
 
1. LOTS Eg. Lifting heavy weights, construction work, labourers, 
running 
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2. MEDIUM Eg. Bike riding, rickshaw drivers, carrying buckets of water or 
loads of laundry to and from wells multiple times a day, 
walking long distances up and down hills 
3. LIGHT 
ACTIVITY 
Eg. Walking on the level, standing all day working at a shop, 
housework such as cooking, cleaning in the house 
4. ALMOST 
NONE 
Eg. Seated at a desk, driving a car, watching television, 
reading, resting 
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17. Have you ever smoked regularly? (i.e. on most days for at least a year) 
 
1. Yes 
2. No 
 
Do you currently 
smoke? 
1.   Yes 
2.   No 
 
1. How many years have you 
smoked for? 
 
|__|     | 
2. How many of each do you 
smoke per day? 
 
 Cigarettes |__|     | 
 
Cigars |__|     | 
 
18. Do you use chewing tobacco regularly? (i.e. on most days for at least a year) 
1.   Yes 
2.   No 
 
19. 
How many people smoke in your household? (include yourself if you are 
a current smoker) 
 
20.  On average, how many hours a day can you smell tobacco smoke at home 
(either your own or others) 
 
 
 
 
 
 
 
|         | 
people 
 
|__|    | hours 
|__|            | minutes
21.  On average, how many hours a day can you smell tobacco smoke at work 
(either your own or others) 
|__|    | hours 
|__|    | minutes
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23.  On average, how many days in a week do you eat fruit?                                   |         | 
days 
 
24.  On average, how many days in a week do you eat green leafy vegetables?     |         | 
days 
 
 
 
I AM NOW GOING TO ASK YOU ABOUT TREATMENTS YOU RECEIVE: 
 
 
 
25.  No        Yes        Have you ever had your BLOOD PRESSURE checked? 
 
 
 
Yes No Was your BP checked by the Byrraju Foundation? 
Yes No Was your BP checked in the last 12 months? 
Yes No Are you taking BP- lowering tablets? 
 
 
Yes No          Are these tablets from the Byrraju 
foundation? 
 
 
26.  No        Yes        Have you ever had your BLOOD SUGAR checked? 
 
 
 
Yes No Was your sugar checked by the Byrraju Foundation? 
Yes No Was your sugar checked in the last 12 months? 
Yes No Are you taking sugar-lowering tablets? 
 
Yes No          Are these tablets from the Byrraju 
foundation? 
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27.  No        Yes        Have you ever had your CHOLESTEROL checked? 
 
 
 
Yes No Was your cholesterol checked in the last 12 months? 
Yes No Are you taking cholesterol lowering tablets? 
 
 
 
 
 
 
28.     Yes          No          Do you take aspirin?
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29. Are you taking any medications regularly? 
1.   Yes 
2.   No 
A. What medications are you taking? (Please write the 
exact name of the medication from the medicine packet 
or a doctor’s script.) 
code 
1.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
2.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
3.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
4.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
5.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
6.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
7.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
8.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
9.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
 
10.  
|__|    |    |    |     |    |            |            |           |            |           |            |            |            |    |    |    |     | 
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I AM NOW GOING TO ASK YOU SOME QUESTIONS ABOUT HEALTH 
SYMPTOMS: 
 
 
 
30. Have you ever had any pain or discomfort or any pressure or a feeling of 
heaviness in your chest? 
1.   Yes 
2.   No                       1.   Do you get it when you walk uphill or 
hurry?                                                        Yes              No 
 
2.   Do you get it when you walk at an 
ordinary pace on the level?                       Yes              No
 
3.   What do you do if you get it while you 
 
Stop or slow down
are walking?                                              
Carry on
4.   If you stand still what happens to it? 
 
 
 
6.   How soon? 
 
 
 
7. Will you show me where it 
was?  MARK THE AREA(S) 
ON THE DIAGRAM 
 
Relieved 
 
Not relieved 
 
10 minutes or less 
 
More than 10 minutes
 
 
 
 
8. Have you ever had a severe chest pain 
across the front of your chest lasting 
for 30 minutes or more? 
 
 
Yes              No
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31. Do you get more breathless than people your own age when you go walking 
either on the level or up a hill? 
1.   Yes 
2.   No
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1. Lose weight Yes No Unsure 
2. Quit smoking Yes No Unsure 
3. Increase exercise Yes No Unsure 
4. Eat more fish Yes No Unsure 
5. Drink less alcohol Yes No Unsure 
6. Reduce fat in meals Yes No Unsure 
7. Reduce salt in meals Yes No Unsure 
8. Eat more fresh fruit Yes No Unsure 
9. Eat more green leafy vegetables Yes No Unsure 
 
1. Lose weight Yes No Unsure 
2. Quit smoking Yes No Unsure 
3. Increase exercise Yes No Unsure 
4. Eat more fish Yes No Unsure 
5. Drink less alcohol Yes No Unsure 
6. Reduce fat in meals Yes No Unsure 
7. Reduce salt in meals Yes No Unsure 
8. Eat more fresh fruit Yes No Unsure 
9. Eat more green leafy vegetables Yes No Unsure 
 
 
Sex (M or F) 
I AM NOW GOING TO ASK YOU SOME QUESTIONS ABOUT DISEASE 
PREVENTION 
 
 
32. Which of the following actions may prevent a person getting a heart attack or 
stroke? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33. In the last 12 months, have you done any of the following to improve your 
health? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34. During the past 12 months have you been hurt in any way which required 
you to seek medical attention, or to stay away from work or school for at 
least one day? This includes you being hurt by an object or by a person (eg 
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Name (BLOCK 
LETTERS) 
 
|__|            |            |            |             |            |            |            |            |            |            |            |     | 
Signature  
 
pushed or hit), or from a fall, road accident, burn, electric shock, poisoning, 
animal bite or drowning. Include injuries that needed medical attention but you 
did not receive treatment due to cost. 
1.   Yes
2.   No 
 
. 
 
If YES, complete the supplementary injury questionnaire 
AFTER you finish the main questionnaire
 
THANK YOU VERY MUCH FOR YOUR TIME, YOU NOW NEED TO GO TO THE EXAMINATION ROOM 
 
 
35. Interviewer Sign off
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41. 
 
Fasting for > 6 hours 
 
Yes 
 
No 
42. Blood sample taken Yes No 
43. Splitting sample Yes No 
44. Urine dipstick Yes No 
 
 
Sex (M or F)               
 
 
DOCUMENTATION OF PHYSICAL EXAMINATION 
 
36. 
 
Height in centimetres 
 
|__|            |     | 
37. Weight in kilograms |__|            |     | 
38. Waist circumference in centimetres |__|            |     | 
39. Hip circumference in centimetres |__|            |     | 
40.      Blood pressure in millimetres of mercury and heart rate 
 
 Time BP taken Systolic Diastolic Heart rate 
I |__|            |            | |    |            |     | |__|            |     | |__|            |     | 
 
II 
 
|__|            |     | 
 
|__|            |     | 
 
|__|            |     | 
 
|__|            |     | 
 
 
 
 
 
 
 
 
 
 Result 
Blood  
Glucose  
Protein  
 
 
45.      ECG                           Yes                 No 
 
46.      Researcher - sign off for physical examination 
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Researcher’s name |__|            |            |            |             |            |            |            |            |            |            |            |     | 
Signature  
Date signed |__|            |/|__|            |/|__|            |            |     | 
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Appendix 3. GC13 Survey Questionnaire  
 
Relevant questions for this work are included below: 
 
Demographics Module 
 
Includes: Introduction, Consent, and Demographic Questions; Mortality Module; Coverage Module 
 
Q2000. [INTERVIEWER: RECORD RESPONDENT’S SEX AS OBSERVED]  
1. Male 
2. Female  
 
Q2001. Just to check, could you tell me if you are 15 years or older? 
1. Yes  
2. No [GO BACK TO RANDOM SELECTION PROCESS TO GET CORRECT ELIGIBLE RESPONDENT] 
 
Demographics of the Respondent 
 
Thank you for agreeing to participate in the survey. I would like to start by asking you some background 
questions.  
 
Q2002.   In what year were you born? PROBE WITH EVENT CALENDAR 
___ ___ ___ ___ Year 
 
 PROBING PROCESS TO BE FOLLOWED WHEN YEAR OF BIRTH IS NOT KNOWN: 
How old do you think you are? 
Try to get the best guess to start the probing process.  Based on the response (for example – 70 years), locate 
the event(s) within that timeframe (70 years before the current year) in the event calendar.  Check with the 
respondent if she is aware of that event (if not, identify another event or combination of events within that 
timeframe). Then, using that event ask – 
Were you born before or after (EVENT)? 
Based on the response, ask – 
IF BORN BEFORE THE EVENT, ASK - How old were you at (EVENT)? 
IF BORN AFTER THE EVENT, ASK - How many years after (EVENT) were you born? 
Arrive at the best estimate for the year of birth by narrowing down the time before or after the (EVENT). 
Based on this information, record the current age. 
Q2003.   What is your current marital status? 
1. Never married [GO TO Q2006] 
2. Currently married 
3. Separated 
4. Divorced 
5. Widowed   
6. Cohabiting/living together [GO TO Q2006] 
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Q2004.   In what year did you first marry?  
___ ___ ___ ____  [ENTER 00 IF LESS THAN 1 YEAR] 
 
Q2005.   [ASK EVER MARRIED WOMEN 15-49 ONLY] Have you ever had a pregnancy? 
1. Yes 
2. No 
 
Q2006.   Have you ever attended school? 
1. Yes 
2. No [GO TO Q3000] 
 
Q2007.   What is the highest level of school you attended? 
1. Primary 
2. Secondary 
3. Higher 
 
Q2008.   What is the highest (grade/form/year) you completed at that level? 
Grade/form/year: ___ ___ 
 
 
Coverage Module 
 
Now I’d like to ask you some questions about your health.  I’d like to remind you that the information you 
provide is totally confidential and will not be disclosed to anyone. 
 
GENERAL HEALTH 
 
Q5000. In general, how would you rate your health today? Is it…    
[READ ALL OPTIONS] 
 
1. Excellent 
2. Very Good 
3. Good 
4. Fair 
5. Poor 
 
VISIT TO A HEALTH PROVIDER 
 
Q5001. When was the last time you visited a health provider [or insert a locally specific term for a health 
provider in the “formal”, possibly a trained, licensed practitioner]? 
1. Less than 1 year ago 
2. 1-5 years ago 
3. More than 5 years ago 
4. Never [DO NOT ASK Q5002-Q5004, Q5007-Q5009, Q5012-Q5014, Q5021-Q5022, Q5024-
Q5025, Q5027-Q5028, Q5030-Q5033, Q5045-Q5048] 
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BLOOD PRESSURE 
Now I would like to ask you some questions focused on health conditions that are common around the world. 
 
Q5002. Have you ever had your blood pressure measured by a health provider? 
1. Yes 
2. No [GO TO 5005] 
 
Q5003. In what year was your blood pressure last measured by a health provider? 
Year ___ ___ ___ ___  
 
Q5004. The last time your blood pressure was measured, were you told it was … [READ OPTIONS] 
1. Normal 
2. Higher than normal 
3. Lower than normal 
4. Or were you not told anything?  
 
Q5005. Are you currently taking western medicine to control your blood pressure or prevent high 
blood pressure? 
‘Western’ refers to all western allopathic medicines that the respondent is taking. Do not 
include homeopathic or ayuvedic medicines.  
1. Yes 
2. No 
 
Q5006. Are you currently taking any herbal or traditional remedy to control your blood pressure or prevent 
high blood pressure?  
 
‘Herbal or traditional remedy’ refers to all non-western medicine, including 
homeopathic, ayuvedic, and any other local traditional medicines. 
1. Yes 
2. No 
 
CHOLESTEROL 
 
Q5007. Have you ever had your blood cholesterol checked by a health provider? 
‘Cholesterol’ is a substance found among the fats in the bloodstream that is an important 
part of a healthy body, but can be dangerous to health if levels are too high. 
1. Yes  
2. No [GO TO Q5010] 
 
Q5008. In what year was your cholesterol last checked by a health provider?  
Year ___ ___ ___ ___  
 
Q5009. The last time your cholesterol was checked, were you told it was … [READ OPTIONS] 
1. Normal 
2. Higher than normal 
3. Lower than normal 
4. Or were you not told anything?  
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Q5010. Are you currently taking western medicine to help control your cholesterol or prevent 
high cholesterol? 
1. Yes 
2. No 
 
Q5011. Taking any herbal or traditional remedy?  
‘Herbal or traditional remedy’ refers to all non-western medicine, including 
homeopathic, ayuvedic, and any other local traditional medicines. 
1. Yes 
2. No 
 
DIABETES  
 
Q5012. Have you ever had a blood test or urine test for diabetes? 
1. Yes 
2. No [GO TO Q5015] 
 
       Q5013. In what year were you last tested for diabetes?   
Year ___ ___ ___ ___  
 
Q5014. Have you ever been told by a health provider that you had diabetes, pre-diabetes or 
borderline diabetes, or diabetes but only at a time when you were pregnant? 
 
1. No 
2. Diabetes 
3. Pre-diabetes or borderline diabetes 
4.  [Women only] Diabetes, but only at a time when you were pregnant 
 
 
Q5015. Are you currently taking diabetic pills? 
1. Yes 
2. No 
 
Q5016. Are you currently taking insulin?  
1. Yes 
2. No 
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HEALTH BEHAVIOR QUESTIONS 
 
Q5017a. Are you currently controlling your weight or losing weight? 
1. Yes 
2. No [GOTO Q5018a] 
 
Q5017b. Why are you currently controlling your weight? Is it because… 
[INTERVIEWER: CHECK ALL THAT APPLY] 
1. Your health provider has recommended you to do so, or  
2. You think it’s good for you 
 
Q5018a. Are you currently increasing your physical activity or exercise? 
1. Yes 
2. No [GOTO Q5019a] 
 
Q5018b. Why are you currently increasing your physical activity or exercise? Is it because… 
[INTERVIEWER: CHECK ALL THAT APPLY] 
1. Your health provider has recommended you to do so, or  
2. You think it’s good for you 
 
Q5019a. Are you currently trying to cutting down on salt? For example, have you cut down on how much 
[insert site-specific salty foods] you eat? 
1. Yes 
2. No [GOTO Q5020a] 
 
Q5019b. Why are you currently trying to cut down on salt? Is it because… 
[INTERVIEWER: CHECK ALL THAT APPLY] 
1. Your health provider has recommended you to do so, or  
2. You think it’s good for you 
 
Q5020a. Are you currently trying to eat fewer high fat or high cholesterol foods? For example, you have cut 
down on how much [insert site-specific high fat/high cholesterol foods] you eat? 
1. Yes 
2. No [GOTO Q5021] 
 
Q5020b. Why are you currently trying to eat fewer high fat or high cholesterol foods? Is it because… 
[CHECK ALL THAT APPLY] 
1. Your health provider has recommended you to do so, or 
2. You think it’s good for you 
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ANGINA  
 
Q5027. Have you ever been told by a health provider that you have angina (or angina pectoris)? 
‘Angina’ is a condition that is characterized by chest pain originating from the heart muscle. 
1. Yes 
2. No [GO TO Q5029] 
 
       Q5028. In what year were you told by a health provider that you have angina? 
Year ___ ___ ___ ___  
 
Q5029. Are you currently taking western medication for angina? 
1. Yes 
2. No 
 
OTHER CHRONIC CONDITIONS 
 
Q5030. Have you ever been told by a health provider that you had a heart attack? 
‘Heart attack’ refers to a myocardial infarction. This is a health condition where the blood 
supply to part of the heart is interrupted, so that the heart does not get enough oxygen and 
can become damaged. 
1. Yes 
2. No 
 
Q5031. Have you ever been told by a health provider that you had a stroke?  
‘Stroke’ refers to a disturbance in the blood supply to the brain. 
1. Yes 
2. No 
 
 
TOBACCO 
 
Q5053. Have you smoked at least 100 cigarettes or beedis [term can be translated to site-
specific terminology for hand-rolled cigarettes throughout this section of questionnaire] in your 
entire lifetime? 
1. Yes 
2. No  
 
Q5054. Do you currently smoke cigarettes/beedis? 
1. Yes 
2. No 
 
[IF RESPONDENT ANSWERED “NO” TO Q5053 and Q5054, GO TO Q5057] 
  
Q5055. How old were you when you first began smoking? 
1.  Age: ____  
2. Don’t know 
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Q5056. How many cigarettes do(did) you smoke a day? 
 
Enter number of cigarettes: ___ ___ 
 
Q5057. [ASK ONLY IF Q5054=1] Do you use any other kind of tobacco? [Add/modify site-specific 
types of tobacco.] 
 [CHECK ALL THAT APPLY] 
1. Pipe 
2. Chewing tobacco 
3. Local form of tobacco 
4. Other 
 
SYMPTOM QUESTIONS 
 
During the last 12 months, have you experienced any of the following:  
 
 
       Q5064. A feeling of tightness in your chest? 
1. Yes 
2. No 
 
Q5065. Waking up with a feeling of tightness in your chest in the morning or any other time? 
1. Yes 
2. No 
 
 
Q5067. Pain or discomfort in your chest when you walk uphill or hurry?  
1. Yes 
2. No 
3. Never walks uphill or hurries 
 
Q5068. Pain or discomfort in your chest when you walk at an ordinary pace on level ground? 
1. Yes 
2. No 
 
 [IF NO TO BOTH Q5067 and Q5068, GO TO Q5072] 
 
       Q5069. What do you do if you get the pain or discomfort when you are walking? 
1. Stop or slow down 
2. Carry on after taking a pain relieving medicine that dissolves in your mouth 
3. Carry on 
 
Q5070. If you stand still, what happens to the pain or discomfort? Is it… 
1. Relieved  
2. Not relieved 
 
Q5071. Will you show me where you usually experience the pain or discomfort?  
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[INTERVIEWER: SHOW FIGURE 2, PICTURE OF CHEST] 
       [RECORD ALL AREAS OF BODY MENTIONED OR SHOWED] 
 
 
1. 
2. 
3.  
4.  
5. 
6. 
7. 
8. 
 
 
 
  
 Page 83 of 93 
 
 
In your lifetime: 
 
Q5074. Have you ever had sudden painless weakness on one side of your body? 
1. Yes 
2. No 
 
Q5075. Have you ever had sudden numbness or a dead feeling on one side of your body? 
1. Yes 
2. No 
 
 Q5076. Have you ever had sudden painless loss of vision in one or both eyes? 
1.    Yes 
2.    No 
 
 Q5077. Have you ever suddenly lost one half of your vision? 
1. Yes 
2. No 
 
 Q5078. Have you ever suddenly lost the ability to understand what people are saying? 
1. Yes 
2. No 
 
Q5079. Have you ever suddenly lost the ability to express yourself verbally or in writing? 
1. Yes 
2. No 
 
INVENTORY OF MEDICINE 
 
We are interested in knowing about the availability and use of certain medicines and drugs. Remember that 
whatever information you give me is confidential and will only be used for research purposes. 
 
 Q5080. Do you have any medicines in the house that a health provider has prescribed for you or 
given to you?  
1. Yes 
2. No  [IF NO, GO TO CLOSE-ENDED QUESTIONS TO THE INTERVIEWER] 
 
Q5081. May I see what medicines you personally have been using in the last 2 weeks?  
1. Yes 
2. No, not using any [GO TO CLOSE-ENDED QUESTIONS TO INTERVIEWER] 
3. Refuse [GO TO CLOSE-ENDED QUESTIONS TO INTERVIEWER] 
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Q5082. [INTERVIEWER: ASK THE RESPONDENT IF YOU CAN SEE THE MEDICATION AND RECORD 
NAME OF PRESCRIPTION OR ANY OTHER RELEVANT INFORMATION FROM THE PRESCRIPTION OR 
BOTTLE/BOX LABEL. IF THE RESPONDENT REFUSES TO ALLOW YOU TO SEE THE MEDICATION, 
SKIP THAT MEDICATION(S)]  
 
1. Name of prescription from bottle/label:__________________ [we will need site to 
code] 
1. How frequently do you use this medicine?  
__times per day OR 
__times per week OR 
__when needed/symptoms occur 
 
2. Name of prescription from bottle/label:__________________ [we will need site to 
code] 
2. How frequently do you use this medicine?  
__times per day OR 
__times per week OR 
__when needed/symptoms occur 
 
3. Name of prescription from bottle/label:__________________ [we will need site to 
code] 
3. How frequently do you use this medicine?  
__times per day OR 
__times per week OR 
__when needed/symptoms occur 
 
4. Name of prescription from bottle/label:__________________ [we will need site to 
code] 
4. How frequently do you use this medicine?  
__times per day OR 
__times per week OR 
__when needed/symptoms occur 
 
5. Name of prescription from bottle/label:__________________ [we will need site to 
code] 
5. How frequently do you use this medicine?  
__times per day OR 
__times per week OR 
__when needed/symptoms occur 
 
[Close-ended question to the interviewer: DO NOT READ OUT LOUD]  Is there anything the research team 
should be aware of about this respondent that may have affected the quality of data? 
1. No significant problems 
2. Respondent seemed to have difficulty understanding 
3. Respondent seemed distracted 
4. Respondent seemed tired 
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5. Respondent seemed drunk  
6. Respondent seemed rushed 
7. Other, specify: 
________________________________________________________________ 
 
PROGRAM CHECK:  
 
 IS THE RESPONDENT A FEMALE? 
 IS THE RESPONDENT 15-49 YEARS OLD? 
 HAS THE RESPONDENT EVER BEEN MARRIED?  
 HAS THE RESPONDEN EVER HAD A PREGNANCY? 
 
IF YES TO ALL ABOVE, GO TO MATERNAL AND CHILD HEALTH MODULE. 
 
OTHERWISE, PROCEED TO PHYSICAL MEASUREMENTS 
 
 
PHYSICAL MEASUREMENTS 
 
INTERVIEWER: PLEASE TAKE HEIGHT, WEIGHT, AND BLOOD PRESSURE MEASUREMENTS AND RECORD BELOW. 
 
PM1. Height [ENTER 9999 FOR REFUSED] 
 
Enter height in centimeters: ___ ___ ___.___ cm 
 
PM2. Weight [ENTER 9999 FOR REFUSED] 
 
Enter weight in kilograms: ___ ___ ___. ___ kg 
 
PM3a. Blood pressure, 1st measurement [ENTER 999 FOR REFUSED] 
 
Systolic: ___ ___ ___ 
Diastolic: ___ ___ ___ 
 
PM3b. Blood pressure, 2nd measurement [ENTER 999 FOR REFUSED] 
 
Systolic: ___ ___ ___ 
Diastolic: ___ ___ ___ 
 
PM3c. Blood pressure, 3rd measurement [ENTER 999 FOR REFUSED] 
 
Systolic: ___ ___ ___ 
Diastolic: ___ ___ ___ 
 
 
IF RESPONDENT NOT SELECTED FOR DBS, THAT COMPLETES THE INTERVIEW 
 
IF RESPONDENT IS SELECTED FOR DBS, PROCEED 
 
PM4. How many hours ago did you last eat or drink anything other than water? 
  ____ hours 
 
 
PM5. Dried blood spots:  
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1. Dried blood spots taken, enter barcode number for DBS: XXXXX- ___ ___ ___ ___ 
2. Refused 
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Appendix 4. SMARTHealth 2014 Survey Questionnaire  
 
Relevant questions for this work is included below: 
 
     Page 1 of the app: 
Welcome page: 5 digits unique combination of alphabets and numeric username and password will be 
provided to log in as Interviewer.  
 
Page 1:  
 
PHC ID: Two digits numeric ID, will be provided to interviewers. [Dropdown] 
Village ID: Two digits numeric ID, will be provided to interviewers. [Dropdown] 
Locality: Select the locality from a pre-populated list. [Dropdown] 
 
Household ID: Nine digits numeric ID (1 digit uniform +2 digits PHC id+2 digits Village id+ 4 digits HH 
id), will be provided to interviewers based on the listing sheet. 
To click search with above details   
 
(Pre filled respondents names will come here, except Village option we can put other 
options here)  
 
Q1: Could you please tell me your house number? 
 
Interviewers will confirm names displayed under the House hold, if given names are not available 
there then interviewer will choose the House hold disposition code:  
 
Household disposition code 
a. Household moved away permanently from the village and a new family is staying[option 
to enter details of eligible individuals in the new household] 
b. New household[option to enter details of eligible individuals in the new household] 
c. Household refused to participate [close the interview] 
 
Q2: List of all members (name, age and gender) aged 40 and above in the household?  
The interviewer selects a particular member to enter his details. Upon end of the questionnaire, 
he/she will be directed back to this page if there is another member whose details have to be 
collected.  
[The head of the household needs to be highlighted either with a star at the end] 
 [Another 2 columns with interview status and respondent disposition code for each respondent] 
Respondent disposition code for interview not done 
a. Respondent not at home during the visit [option to click on this respondent on next 
visit] 
b. Respondent moved away permanently [name is greyed out] 
c. Respondent not eligible [name is greyed out] 
d. Respondent is not alive [name is greyed out] 
e. Respondent incapacitated [name is greyed out]  
f. Respondent refuses to participate [option to click on this respondent on next visit] 
If the house hold member gives consent and agrees to participate in the study Interviewer need to click Start 
New Risk Assessment to initiate the screening.  
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Page 2 of the app: 
Participant ID: eleven  digits numeric ID, first digit 1 is uniform to all IDs, second 2 digits – village id, 
next four digits - household, last two digits individual order in the household – [automatically 
generated from the household number] 
Consent Number:5 digits alphanumeric ID, type in the consent number on the top of the consent 
form 
Q3: Just to check, could you please tell us your name? 
[Interviewers to first record his/her surname and then the given name] 
Sex (male/female) to appear on this screen 
Q4: What is your date of Birth? (Date /Month /Year)? 
If date of birth is not known, what is your age? 
[Interviewer will use “I” button to check Event calendar for males and age probing methods for 
females to get accurate age in case the respondents do not remember their date of birth or age. 
Age is collected again during the baseline study to confirm the age we have recorded during the 
listing. At this point, if it is found that the respondent is less than 40 years old, the interviewer will 
thank and terminate the Interviewer] 
Q5: What is your current marital status? [Responses in drop down box] 
1. Single  
2. Married 
3. Separated 
4. Divorced 
5. Widowed 
Q6: What is the highest level of formal education you have obtained?[Responses in drop down box] 
1. No School. 
2. Primary  (till 5th class) 
3. Upper Primary (till 7th class) 
4. Secondary School (up to 10th class) 
5. Higher Secondary (Intermediate) 
6. Graduate & Higher 
Q7: What is your present occupation? [Responses in drop down box] 
 
1. Agriculture Labourer 
2. Manual Labourer 
3. Skilled worker 
4. Farmer  
5. Business 
6. Housewife 
7. Retired 
8. Government Employee   
9. Others  
Page 3 of the app: 
Past History 
Interviewer: Have you ever been told by a health provider that you have or have had any of following  
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“I” button will be used by interviewer to make uniform explanation about the diseases/condition, 
interviewer will read the message in “I” button as it is to explain to the respondent.  
Q8: Have you ever been told by a health provider that you have or have had heart attack or angina? 
1. Yes [go to q 8b] 
0. No 
8b: When were you told - ____________ years ago [drop down box – 1,2,3,4,5,>5   year ago, don’t know] 
    
Q9: Have you ever been told by a doctor that you have or have had Stroke? 
1. Yes [go to q 9b] 
0. No 
9b. When were you told ____________ years ago [drop down box – 1,2,3,4,5,>5  year ago,  don’t know] 
 
Q10. Have you ever been told by a doctor that you have or have had Diabetes? 
1. Yes [go to q 10b] 
0. No 
10b. When was it done - ____________ years ago [drop down box – 1,2,3,4,5,>5 year ago, don’t know] 
Q11: Have you ever been told by a doctor that you have or have had Hypertension (High BP)  
1. Yes [go to q 11b] 
0. No 
11b. When were you told - ____________ years ago [drop down box – 1,2,3,4,5,>5 year ago, don’t know] 
Q12: Have you ever had a surgery done in legs to restore blood flow by redirecting blood around the blocked 
or narrowed artery? Peripheral vascular diseases  
1. Yes [go to q 11b] 
0. No 
12b. When were you told - ____________ years ago [drop down box – 1,2,3,4,5,>5 year ago, don’t know] 
 
Family History 
Interviewer: Have any one of your close relatives (mother, father, brother, sister) had ever suffered from 
any of the following  
Q13: Have any one of your close relatives (mother, father, brother, sister) had ever suffered from heart 
attack? 
1. Yes 
0. No 
Q14: Have any one of your close relatives (mother, father, brother, sister) had ever suffered from stroke? 
1. Yes 
0. No 
Q15: Have any one of your close relatives (mother, father, brother, sisters) had suffered from Diabetes? 
1. Yes 
0. No 
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Smoking Status  
Q16: Have you ever used tobacco products in any form  
1. Smoking cigarette/Beedi/Chutta 
2. Chewing tobacco like Khaini/Ghutka/Zarda 
3. Both 
4. No [Go to next section] 
If smoking cigarette/Beedi/Chutta: 
Q16a: Do you currently smoke cigarettes/Beedi/Chutta (at least 1 per day)? 
1. Yes [GO TO Q16c] 
0. No [GO TO Q16b] 
 
Q16b: Did you quit smoking cigarettes/Beedi/Chutta in last 12 months? 
1. Yes [GO TO Q18c] 
0. No [Go to Q19a] 
 
Q16c: Age when you started smoking?   _____ years. 
 
If chewing tobacco: 
 
Q17a. Do you currently chew tobacco? 
 
1. Yes [GO TO Q17c] 
0. No [GO TO Q17b] 
 
Q17b: Did you quit chewing tobacco in last 12 months? 
1. Yes [GO TO Q17c] 
0. No [Go to next section] 
 
Q17c: Age when you started chewing tobacco?   _____ Years. 
 
If the respondent using both:  
Q18. Do you currently smoke and chew tobacco both? 
               Interviewer will get both Questions 16b, c and 17 b,c to fill in.  
 
Page 4 
CVD Risk Factor Measurements 
Interviewer: Now I am going to measure your Blood Pressure 3 times with this instrument. Please be seated 
comfortably, [BP VALUES ARE AUTOMATICALLY TRANSFERRED INTO APPLICATION] 
“I” info button explains about how to check blood pressure and using A&D BP machine.  
Blood Pressure  
1st Measurement       SBP___  /DBP____mmHg             HR___bpm  
2nd Measurement       SBP___   /DBP____mmHg            HR___bpm 
3rd Measurement       SBP___   / DBP____ mmHg          HR___bpm 
Cuff size used:  
Acquire 
Acquire 
Acquire 
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1. Standard  
2. Large  
Blood Glucose: 
Now I am going collect one drop of blood from your finger by prick with sterilized lancet to measure your 
blood glucose level. 
 
Blood Glucose Values __________mg/dl 
 
Q 19. How many hours ago did you last eat or drink anything other than water _______ hrs  
              Select from the drop down list:  
1. 0-2 hr. 
 2. 2-4 hr.  
3. 4-6 hr.  
4. >6 hours.  
              Time of day blood specimen taken (24 hour clock) – Automatically records time 
 
Page 5 of the app: 
 
Referral to Doctor recommended due to presence of the following 
 SBP > 180 or DBP >100 mm /hg  
 FBG >____ or RBS > ________ mg/dl 
 
PROFILING (PROGRAM CHECK):  
 HAS THE RESPONDENT CONFIRMED OF AN ESTABLISHED CVD (EITHER CORONARY 
HEART DISEASE, STROKE/ TRANSIENT ISCHEMIC ATTACK OR PERIPHERAL VASCULAR 
DISEASE)? 
 IS THE RESPONDENT’S TEN-YEAR CVD RISK ≥30%? 
 IS THE RESPONDENT’S TEN-YEAR CVD RISK ≥20% AND A SYSTOLIC BLOOD PRESSURE 
(SBP) ≥ 140mmHg?  
IF YES TO ANY OF THE ABOVE, GO TO THE MODULE FOR FURTHER QUESTIONS. 
IF NOT:   
END THE SURVEY HERE 
[Thank you for answering all the questions. We appreciate your participation in this study and will 
give you the results of the measurements right away. Please feel free to ask any questions that you 
might have]  
Page 6 of the app: Further Questions: 
IF RESPONDENT IS SELECTED FOR FURTHER QUESTIONS: 
[Thank you for answering all the questions. As I mentioned before, in this study, we are also trying to collect 
more information about your health.  Therefore, we would like to ask you some more questions about your 
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health. We will also measure your height and weight. I would like to remind you that the information you 
provide is totally confidential and will not be disclosed to anyone]  
Medicine history: 
Q22a: Are you currently on any of following medication? 
 “I” button gives commonly available different type of BP Lowering medicines just to get an idea for 
Interviewer 
May I see what medicines you have been using? [Interviewer to see the medication and record name 
of the medication from the bottle/strip label] 
1. BP Lowering medication  
1 Yes  
0 No  
2. Lipid Lowering medication ( Statin)  
1 Yes  
0. No  
3. Anti-plate let Therapy  
1 Yes  
0 No  
If Yes there will be pop up question comes on  
22b.Record Medication use:   
o Information available  
o Currently not available  
o Refused to show  
If Information is available Input Medication box will be prepopulated to enter the details of Medication as 
follows:  
 
Q22b: Could you please tell me the number of tablets/medicines you are currently consuming in a day? 
 
[All the medications from Q22a should appear below] 
 
1. Brand Name _____number of pills in a day_____strength____ 
                        Press         to Save medication details or Cancel to delete.   
2. Brand Name _____number of pills in a day_____strength____ 
 
Q23: Do you take herbal or AYUSH medicine? 
1. Yes 
0. No  
 
Page 7 of the app:  
Q24: Physical activity :( We modified the shorter version of IPAQ) 
1. How many days in the past week have you done vigorous physical activity?  
”I” Button: explains more about what is vigorous activity 
o Number of Days per week [if >=1,  go to q 1b. If no go to q 2] [range check – 1 to 7] 
o No vigorous activity 
o Don’t know/not sure 
o Refused 
 
1b. Time spent on one of those days: _____Hours ______mins 
 
2. How many days in the past week have you done moderate physical activity?  
Input Medication  
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o Number of Days per week [if >=1,  go to q 2b. If no go to q 3] [range check – 1 to 7] 
o No vigorous activity 
o Don’t know/not sure 
o Refused 
 
2b. Time spent on one of those days: _____Hours ______mins 
 
3. How many days in the past week have you walked (with the duration being at least 10 minutes or more 
per walk)  
 
o Number of Days per week [if >=1,  go to q 2b. If no go to Q 25] [range check – 1 to 7] 
o No vigorous activity 
o Don’t know/not sure 
o Refused 
 
3b. Time spent on one of those days: _____Hours ______mins 
 
 
 
 
 
 
 
 
   
 
Q27. Physical Measurements:  
“I” button will explain record height and weight measures in the given blanks.  
Height _____ cms 
Weight  _____ kgs 
Page 12 of the app:  
If the patient is identified as high risk, an alert appears -  
 Referral to a doctor is recommended.  
If the patient doesn’t fall under high risk then the following message appears -  
Thank you for answering all the questions. We appreciate your participation in this study and will give you 
the results of the measurements right away. Please feel free to ask any questions that you might have.  
 CLICK OK TO SAVE THE CASE.  
 
 
 
 
 
OK 
